Balchem (BCPC) 10-K 21 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 07, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-13648
Entity Registrant Name	Balchem Corporation
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	13-2578432
Entity Address, Address Line One	5 Paragon Drive
Entity Address, City or Town	Montvale
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07645
City Area Code	845
Local Phone Number	326-5600
Title of 12(b) Security	Common Stock, par value $.06-2/3 per share
Trading Symbol	BCPC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Small Reporting Company	false
Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 4,969
Entity Common Stock, Shares Outstanding		32,532,724
Documents Incorporated by Reference	Selected portions of the Registrant’s proxy statement for its 2025 Annual Meeting of Shareholders (the “2025 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2024 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein.
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Central Index Key	0000009326

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor Information [Abstract]
Auditor Name	RSM US LLP
Auditor Firm ID	49
Auditor Location	New York, New York

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 49,515	$ 64,447
Accounts receivable, net of allowance for credit losses of $909 and $908 at December 31, 2024 and 2023, respectively	119,662	125,284
Inventories, net	130,802	109,521
Prepaid expenses	8,054	7,798
Other current assets	5,737	7,192
Total current assets	313,770	314,242
Property, plant and equipment, net	282,154	276,039
Goodwill	780,030	778,907
Intangible assets with finite lives, net	165,050	191,212
Right of use assets - operating leases	15,320	17,763
Right of use assets - finance lease	1,730	2,101
Other non-current assets	17,317	16,947
Total assets	1,575,371	1,597,211
Current liabilities:
Trade accounts payable	54,745	55,503
Accrued expenses	43,750	40,855
Accrued compensation and other benefits	22,886	17,228
Dividends payable	28,510	25,717
Income tax payable	4,466	4,967
Operating lease liabilities - current	3,134	3,949
Finance lease liabilities - current	194	272
Total current liabilities	157,685	148,491
Revolving loan	190,000	309,569
Deferred income taxes	43,722	52,046
Operating lease liabilities - non-current	12,967	14,601
Finance lease liabilities - non-current	1,749	1,943
Other long-term obligations	19,335	16,577
Total liabilities	425,458	543,227
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,527,244 shares issued and outstanding at December 31, 2024 and 32,254,728 shares issued and outstanding at December 31, 2023, respectively	2,170	2,152
Additional paid-in capital	173,997	145,653
Retained earnings	997,493	897,488
Accumulated other comprehensive (loss) income	(23,747)	8,691
Total stockholders’ equity	1,149,913	1,053,984
Total liabilities and stockholders’ equity	$ 1,575,371	$ 1,597,211

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 909	$ 908
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,527,244	32,254,728
Common stock, shares outstanding (in shares)	32,527,244	32,254,728

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net sales	$ 953,684	$ 922,439	$ 942,358
Cost of sales	617,478	620,383	661,907
Gross margin	336,206	302,056	280,451
Operating expenses:
Selling expenses	68,916	74,397	67,409
Research and development expenses	16,793	15,049	12,191
General and administrative expenses	67,588	53,417	55,665
Total operating expenses	153,297	142,863	135,265
Earnings from operations	182,909	159,193	145,186
Other expenses:
Interest expense, net	16,528	22,613	10,268
Other (income) expense, net	(72)	(681)	1,169
Total other expenses	16,456	21,932	11,437
Earnings before income tax expense	166,453	137,261	133,749
Income tax expense	37,978	28,718	28,382
Net earnings	$ 128,475	$ 108,543	$ 105,367
Basic net earnings per common share (in dollars per share)	$ 3.97	$ 3.38	$ 3.29
Diluted net earnings per common share (in dollars per share)	$ 3.93	$ 3.35	$ 3.25

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net earnings	$ 128,475	$ 108,543	$ 105,367
Other comprehensive (loss) income, net of tax:
Net foreign currency translation adjustment	(32,590)	16,809	(4,799)
Unrealized (loss) gain on cash flow hedge, net of taxes of $341, and $868 at December 31, 2023, and 2022, respectively	0	(1,065)	2,696
Net change in postretirement benefit plan, net of taxes of $44, $39, and $24 at December 31, 2024, 2023 and 2022, respectively	152	101	(58)
Other comprehensive (loss) income, net of tax	(32,438)	15,845	(2,161)
Comprehensive income	$ 96,037	$ 124,388	$ 103,206

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other comprehensive (loss) income, net of tax:
Unrealized gain/(loss) on cash flow hedge taxes	$ 0	$ (341)	$ 868
Net change in postretirement benefit plan taxes	$ 44	$ 39	$ 24

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2021	$ 877,015	$ 732,138	$ (4,993)	$ 2,154	$ 147,716
Beginning balance (in shares) at Dec. 31, 2021				32,287,150
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	105,367	105,367
Other comprehensive (loss) income	(2,161)		(2,161)
Dividends	(23,018)	(23,018)
Repurchases of common stock	(35,423)			$ (16)	(35,407)
Repurchases of common stock (in shares)				(252,304)
Shares and options issued under stock plans	16,504			$ 7	16,497
Shares and options issued under stock plans (in shares)				117,941
Ending balance at Dec. 31, 2022	938,284	814,487	(7,154)	$ 2,145	128,806
Ending balance (in shares) at Dec. 31, 2022				32,152,787
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	108,543	108,543
Other comprehensive (loss) income	15,845		15,845
Dividends	(25,542)	(25,542)
Repurchases of common stock	(4,514)			$ (2)	(4,512)
Repurchases of common stock (in shares)				(32,558)
Shares and options issued under stock plans	21,368			$ 9	21,359
Shares and options issued under stock plans (in shares)				134,499
Ending balance at Dec. 31, 2023	$ 1,053,984	897,488	8,691	$ 2,152	145,653
Ending balance (in shares) at Dec. 31, 2023	32,254,728			32,254,728
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 128,475	128,475
Other comprehensive (loss) income	(32,438)		(32,438)
Dividends	(28,470)	(28,470)
Repurchases of common stock	(5,682)			$ (3)	(5,679)
Repurchases of common stock (in shares)				(38,922)
Shares and options issued under stock plans	34,044			$ 21	34,023
Shares and options issued under stock plans (in shares)				311,438
Ending balance at Dec. 31, 2024	$ 1,149,913	$ 997,493	$ (23,747)	$ 2,170	$ 173,997
Ending balance (in shares) at Dec. 31, 2024	32,527,244			32,527,244

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Dividends (in dollars per share)	$ 0.87	$ 0.79	$ 0.71

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net earnings	$ 128,475	$ 108,543	$ 105,367
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	47,973	54,935	51,848
Stock compensation expense	16,675	16,052	13,224
Deferred income taxes	(6,779)	(10,814)	(8,362)
Provision for credit losses	299	37	401
Unrealized (gain) loss on foreign currency transactions and deferred compensation	(100)	(733)	914
Asset impairment charge and loss on disposal of assets	1,664	7,031	366
Change in fair value of contingent consideration liability	(91)	(11,300)	0
Changes in assets and liabilities, net of acquired balances
Accounts receivable	5,582	6,969	(3,618)
Inventories	(22,791)	10,530	(7,804)
Prepaid expenses and other current assets	225	(3,540)	1,870
Accounts payable and accrued expenses	9,065	3,552	(15,543)
Income taxes	(583)	2,194	296
Other	2,385	305	(423)
Net cash provided by operating activities	181,999	183,761	138,536
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	(24,164)	(1,252)	(365,780)
Capital expenditures and intangible assets acquired	(35,661)	(37,892)	(49,945)
Proceeds from sale of assets	359	1,881	206
Proceeds from settlement of net investment hedge	0	2,740	0
Investment in affiliates	(270)	(290)	(495)
Net cash used in investing activities	(59,736)	(34,813)	(416,014)
Cash flows from financing activities:
Proceeds from revolving loan	26,000	18,000	435,000
Principal payments on revolving debt	(145,569)	(149,000)	(103,000)
Principal payments on acquired debt	0	0	(30,988)
Cash paid for financing costs	0	0	(1,232)
Principal payments on finance lease	(216)	(222)	(177)
Proceeds from stock options exercised	17,228	5,242	3,212
Dividends paid	(25,576)	(22,872)	(20,713)
Repurchases of common stock	(5,682)	(4,469)	(35,423)
Net cash (used in) provided by financing activities	(133,815)	(153,321)	246,679
Effect of exchange rate changes on cash	(3,380)	2,260	(5,880)
Decrease in cash and cash equivalents	(14,932)	(2,113)	(36,679)
Cash and cash equivalents beginning of period	64,447	66,560	103,239
Cash and cash equivalents end of period	$ 49,515	$ 64,447	$ 66,560

BUSINESS DESCRIPTION AND SUMMAR

BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Description Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical device sterilization industries. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer. In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers , revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S. and other countries exceed the insurance limits of the Federal Deposit Insurance Corporation (“FDIC”) and other relevant insurance limits in other countries. Accounts Receivable Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for credit losses for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required. Inventories Inventories are valued at the lower of cost (first in, first out) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 years Equipment 2-28 years Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations. Business Concentrations Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2024, 2023 and 2022, no customer accounted for more than 10% of total net sales or accounts receivable. Post-employment Benefits We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease. In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. Goodwill and Acquired Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired in accordance with ASC 805, "Business Combinations". Goodwill and intangible assets acquired in a business combination that have indefinite useful lives are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the assets might be impaired, in accordance with the provisions of ASC 350, "Intangibles-Goodwill and Other". The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the assets might be impaired. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. In accordance with this update, a goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. As of October 1, 2024 and 2023, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, certain components of the discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2024 and 2023. The Company may resume performing the qualitative assessment in subsequent periods. The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 - 20 Trademarks and trade names 2 - 17 Developed technology 5 - 12 Regulatory registration costs 5 - 10 Patents and trade secrets 15 - 17 Other 2 - 18 Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2024, there were no triggering events which required intangible asset impairment reviews. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained. Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision. Use of Estimates Management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments. In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement." Cost of Sales Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. Selling, General and Administrative Expenses Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs. Research and Development Research and development costs are associated directly with the Company's efforts to develop, design, and enhance its products, services, technologies, or processes. Such costs are expensed as incurred. Net Earnings Per Common Share Basic net earnings per common share is calculated by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method). Stock-based Compensation The Company has stock-based employee compensation plans, which are described more fully in Note 3, Stockholders' Equity . The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the statement of earnings as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results. Impairment of Long-lived Assets Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. Derivative Instruments and Hedging Activities The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments was to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes. The derivative instruments were with the above single counterparty and were subject to a contractual agreement that provided for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments were categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet. The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2024 and 2023. On a quarterly basis through their maturity, we assessed the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. The hedging relationships were determined to be highly effective. As such, the net change in fair values of the interest rate swap, that qualified as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and subsequently reclassified into interest expense as interest payments were made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remain in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, Derivative Instruments and Hedging Activities , for detailed information about our derivative financial instruments. Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40)." The new guidance is intended to enhance transparency and disclosures by requiring public entities to provide disaggregated disclosures of certain categories of expenses on an annual and interim basis. The ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on the consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment in this Update should be applied on a prospective basis, with retrospective application permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on the consolidated financial statements and related disclosures. Recently Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures." The ASU expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning December 15, 2024. The Company adopted this accounting guidance on December 31, 2024, and applied it retrospectively to all prior periods presented in our consolidated financial statements. Refer to Note 11, Segment Information for the expanded disclosures. In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", and in December 2022 subsequently issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” These ASU’s provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The Standards Updates provide optional expedients and exceptions for applying accounting principles generally accepted in the United States to contract modifications and hedging relationships that reference LIBOR or another reference rate that are expected to be discontinued. The Standards Updates were effective upon issuance and can generally be applied through December 31, 2024. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its interest rate swap and replaced LIBOR with 1-month CME Term SOFR. The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. The interest rate swap matured on June 27, 2023.

SIGNIFICANT ACQUISITIONS

SIGNIFICANT ACQUISITIONS	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
SIGNIFICANT ACQUISITIONS	SIGNIFICANT ACQUISITIONS Cardinal Associates Inc. ("Bergstrom") On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc. ("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc. ("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom"). Bergstrom Nutrition is a leading science-based manufacturer of MSM, based in Vancouver, Washington. MSM is a widely used nutritional ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. The addition of OptiMSM ® , Bergstrom Nutrition's MSM brand, to the Company's portfolio within the Human Nutrition and Health and Animal Nutrition and Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products. The Company made payments of $72,143 for the acquisition, amounting to $71,937 to the former shareholders or on behalf of the former shareholders and $206 to pay off Bergstrom's bank debt. Net of cash acquired of $773, total payments made to the former shareholders or on behalf of the former shareholders of Bergstrom were $71,164. The acquisition was primarily financed through the 2022 Credit Agreement (see Note 8, Revolving Loan ). In connection with this transaction, the former shareholders of Bergstrom had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. The earn-out payment of $9 was paid out in 2024. Therefore, there was no contingent consideration liability at December 31, 2024. The Company also made an additional post-closing payment of $910 in the third quarter of 2023 that was negotiated as a deduction of the cash consideration at closing. As a result, total payments related to the transaction were $72,152, comprised of the upfront cash consideration of $70,892, a working capital adjustment of $341, an additional post-closing payment of $910, and the fair value of the earn-out payment of $9. The goodwill of $31,550 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. 80% of the goodwill is assigned to the Human Nutrition and Health business segment and 20% of the goodwill is assigned to the Animal Nutrition and Health business segment. For tax purposes, a joint election under 338(h)(10) was made to treat the stock acquisition as a deemed asset acquisition, therefore generating tax amortizable goodwill. The following table summarizes the fair values of the assets acquired and liabilities assumed: Cash and cash equivalents $ 773 Accounts receivable 4,699 Inventories 3,972 Property, plant and equipment 2,243 Right of use assets 866 Customer relationships 29,900 Developed technology 4,600 Trademarks 2,300 Other assets 197 Accounts payable (699) Bank debt (206) Lease liabilities (871) Other liabilities (462) Goodwill 31,550 Total consideration on acquisition date and working capital adjustment 78,862 Net decrease to contingent consideration liability and other post-closing payments (6,916) Total consideration 71,946 To pay off bank debt 206 Total payments $ 72,152 The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined. Transaction and integration costs related to the Bergstrom acquisition are included in general and administrative expenses and were $(91), $(10,614) and $4,604 for the years ended December 31, 2024, 2023, and 2022, respectively. These amounts included favorable adjustments to transaction costs of $91 and $11,300 for the years ended December 31, 2024 and 2023 and an unfavorable adjustment to transaction costs of $3,565 for the year ended December 31, 2022. Kechu BidCo AS and Its Subsidiary Companies ("Kappa") On June 21, 2022, Balchem Corporation and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as “Kappa”). Kappa manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition and Health segment. The Company made payments of approximately kr3,305,653 ("kr" indicates the Norwegian krone), amounting to approximately kr3,001,981 to the former shareholders and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments to the former shareholders were kr2,938,917. Net of gains on foreign currency forward contracts of $512 (see Note 20, Derivative Instruments and Hedging Activities ), these payments translated to approximately $333,112, amounting to approximately $302,464 paid to the former shareholders and approximately $30,648 to Kappa's lenders. Net of cash acquired of $6,365, total payments made to the former shareholders of Kappa were approximately $296,099. The acquisition was primarily financed through the 2018 Credit Agreement. In connection with this transaction, the former shareholders of Kappa had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. There was no contingent consideration paid in connection with this acquisition. The goodwill of $216,383 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition and Health business segment and is not deductible for income tax purposes. The following table summarizes the fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022. Cash and cash equivalents $ 6,365 Accounts receivable 8,036 Inventories 17,600 Property, plant and equipment 9,854 Right of use assets 3,349 Customer relationships 88,813 Developed technology 15,643 Trademarks 5,046 Other assets 2,399 Accounts payable (3,301) Bank debt (30,648) Lease liabilities (3,349) Other liabilities (4,461) Deferred income taxes, net (24,716) Goodwill 216,383 Total consideration on acquisition date 307,013 Decrease to contingent consideration liability (4,037) Net gain on foreign currency exchange forward contracts (512) Total consideration 302,464 Kappa bank debt paid on acquisition date 30,648 Total payments $ 333,112 The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined. Transaction and integration costs related to the Kappa acquisition are included in general and administrative expenses and were $688, $533 and $(2,306) for the years ended December 31, 2024, 2023, and 2022, respectively. The amount included a favorable adjustment to transaction costs of $4,037 for the year ended December 31, 2022. The following selected unaudited pro forma information presents the consolidated results of operations as if the business combinations in 2022 had occurred as of January 1, 2021. Twelve Months ended December 31, Net Sales Net Earnings Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023 $ 59,532 $ 5,487 Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2022 $ 22,158 $ (5,359) 2023 Supplemental pro forma combined financial $ 922,439 $ 116,317 2022 Supplemental pro forma combined financial $ 982,021 $ 110,181 2021 Supplemental pro forma combined financial $ 859,252 $ 90,672 The above selected unaudited pro forma information includes the following acquisition-related adjustments: (1) additional amortization of intangible assets and depreciation of fixed assets; (2) adjustments related to the fair value of the acquired inventory, (3) adjustments to interest expense on borrowings at rates in effect during the related period, factoring in estimated payments based on free cash flow, and (4) other one-time adjustments. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if these acquisitions had occurred at the beginning of the periods presented and is not intended to be a projection of future results.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock-Based Compensation All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values. The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest. The Company’s results for the years ended December 31, 2024, 2023 and 2022 reflected the following compensation cost and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the 2024 2023 2022 Cost of sales $ 1,716 $ 1,900 $ 1,302 Operating expenses 14,960 14,152 11,922 Net earnings (12,865) (12,375) (10,214) On December 31, 2024, the Company had one share-based compensation plan under which awards may be granted, which is described below. In June 2017, the Company’s shareholders approved the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired in April 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. On June 22, 2023, the Company’s shareholders approved an amendment and restatement of the 2017 Plan (the “Amended 2017 Plan”). The Amended 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The Amended 2017 Plan provides as follows: (i) for a termination date of June 22, 2033; (ii) the authorization of 2,400,000 shares for future grants (which represents an increase of 800,000 shares from the amount approved under the 2017 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided by the Compensation Committee or in an employment agreement as in effect on the effective date of the Amended 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vi) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for incentive compensation recovery if the Company is required to prepare an accounting restatement of its financial statements, in accordance with any compensation recovery policy adopted by the Company, applicable law, government regulations or national securities exchange requirements, or in the discretion of the Compensation Committee in the event of a restatement due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant. The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2024, the Amended 2017 Plan had 836,521 shares available for future awards. The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements. The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) market condition where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents. The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. For the years ended December 31, 2024, 2023, and 2022, the fair value of each option grant uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life. Year Ended December 31, Weighted Average Assumptions: 2024 2023 2022 Expected Volatility 28.4 % 28.1 % 30.3 % Expected Term (in years) 5.0 4.8 7.3 Risk-Free Interest Rate 4.1 % 3.9 % 2.8 % Dividend Yield 0.6 % 0.5 % 0.5 % The value of the restricted shares is based on the fair value of the award at the date of grant. Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 4.2%, 4.2%, and 1.8%; dividend yields of 0.0%, 0.5%, and 0.5%; volatilities of 25%, 32%, and 32%; and initial TSR’s of 10.3%, 4.2%, and -15.7% in each case for the years ended December 31, 2024, 2023, and 2022, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three A summary of stock option plan activity for 2024, 2023, and 2022 for all plans is as follows: 2024 2023 2022 # of Weighted Average # of Weighted Average # of Weighted Average Outstanding at beginning of year 1,078 $ 104.38 1,045 $ 99.82 867 $ 88.19 Granted 113 143.43 109 138.09 239 139.04 Exercised (221) 77.81 (64) 81.98 (44) 73.58 Forfeited (8) 139.64 (11) 131.79 (17) 124.89 Cancelled — — (1) 138.07 — — Outstanding at end of year 962 $ 114.81 1,078 $ 104.38 1,045 $ 99.82 Exercisable at end of year 603 $ 99.59 720 $ 88.49 654 $ 81.95 The aggregate intrinsic value for outstanding stock options was $46,346, $47,889 and $27,221 at December 31, 2024, 2023 and 2022, respectively, with a weighted average remaining contractual term of 5.8 years at December 31, 2024. Exercisable stock options at December 31, 2024 had an aggregate intrinsic value of $38,221 with a weighted average remaining contractual term of 4.4 years. Other information pertaining to option activity during the years ended December 31, 2024, 2023 and 2022 is as follows: Years Ended December 31, 2024 2023 2022 Weighted-average fair value of options granted $ 44.52 $ 40.91 $ 44.77 Total intrinsic value of stock options exercised ($000s) $ 18,631 $ 3,241 $ 2,713 Additional information related to stock options outstanding under all plans at December 31, 2024 is as follows: Options Outstanding Options Exercisable Range of Exercise Shares Weighted Weighted Number Weighted $58.52 - $85.33 222 3.1 $ 76.14 222 $ 76.14 $85.40 - $118.60 212 4.0 101.92 212 101.92 $118.96 - $150.85 528 7.6 136.24 169 127.47 962 5.8 $ 114.81 603 $ 99.59 Non-vested restricted stock activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Shares (000s) Weighted Shares (000s) Weighted Shares (000s) Weighted Non-vested balance at beginning of year 116 $ 133.06 122 $ 124.42 166 $ 99.70 Granted 51 147.98 40 137.20 46 137.17 Vested (39) 124.63 (42) 112.30 (82) 82.15 Forfeited (6) 140.70 (4) 128.06 (8) 118.07 Non-vested balance at end of year 122 $ 141.62 116 $ 133.06 122 $ 124.42 Non-vested performance share activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Shares (000s) Weighted Shares (000s) Weighted Shares (000s) Weighted Non-vested balance at beginning of year 76 $ 135.25 70 $ 127.69 69 $ 110.72 Granted 47 152.28 42 139.66 39 114.22 Vested (44) 106.57 (36) 98.84 (35) 53.17 Forfeited — — — — (3) 84.09 Non-vested balance at end of year 79 $ 150.73 76 $ 135.25 70 $ 127.69 As of December 31, 2024, 2023 and 2022, there was $20,035, $18,817 and $20,791, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2024, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.5 years. We estimate that share-based compensation expense for the year ended December 31, 2025 will be approximately $16,900. Repurchase of Common Stock

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, net of reserves at December 31, 2024 and 2023 consisted of the following: 2024 2023 Raw materials $ 45,319 $ 39,517 Work in progress 4,510 3,960 Finished goods 80,973 66,044 Total inventories $ 130,802 $ 109,521 On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $4,207 and $2,463 at December 31, 2024 and 2023, respectively.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at December 31, 2024 and 2023 are summarized as follows: 2024 2023 Land $ 11,690 $ 11,787 Building 106,954 104,363 Equipment 315,001 312,704 Construction in progress 77,508 59,981 511,153 488,835 Less: Accumulated depreciation 228,999 212,796 Property, plant and equipment, net $ 282,154 $ 276,039 Geographic Area Data - Long-Lived Assets (excluding intangible assets): 2024 2023 United States $ 204,397 $ 203,692 Foreign Countries 77,757 72,347 Total $ 282,154 $ 276,039 Depreciation expense was $28,211, $26,373 and $24,033 for the years ended December 31, 2024, 2023 and 2022, respectively. In accordance with Topic 360, the Company reviews long-lived assets for impairment on an annual basis and also whenever events indicate that the carrying amount of the assets may not be fully recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. Included in "General and administrative expenses" was $521 of restructuring-related impairment charges related to an asset that was held for sale for the year ended December 31, 2024. Included in “General and administrative expenses” were restructuring-related impairment and asset disposal charges of $7,764 related to building, equipment, and construction in progress mainly in the Human Nutrition and Health and the Animal Nutrition and Health segments for the year ended December 31, 2023. Such expenses were not material for the year ended December 31, 2022.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The Company had goodwill in the amount of $780,030 and $778,907 as of December 31, 2024 and 2023, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is primarily due to an acquisition, partially offset by foreign currency translation adjustments. Goodwill at December 31, 2022 $ 769,509 Goodwill as a result of an acquisition 341 Impact due to change in foreign exchange rates 9,057 Goodwill at December 31, 2023 778,907 Goodwill as a result of an acquisition 19,376 Impact due to change in foreign exchange rates (18,253) Goodwill at December 31, 2024 $ 780,030 December 31, 2024 December 31, 2023 HNH $ 678,275 $ 673,207 ANH 23,974 24,469 Specialty Products 77,732 81,175 Other and Unallocated 49 56 Total $ 780,030 $ 778,907 As of December 31, 2024 and 2023, the Company had identifiable intangible assets as follows: 2024 2023 Amortization Gross Accumulated Gross Accumulated Customer relationships and lists 10-20 $ 354,051 $ 221,567 $ 362,032 $ 209,651 Trademarks and trade names 2-17 50,971 41,417 50,286 37,773 Developed technology 5-12 40,074 20,362 41,184 17,516 Other 2-18 25,154 21,854 25,733 23,083 $ 470,250 $ 305,200 $ 479,235 $ 288,023 Amortization of identifiable intangible assets was $19,244, $28,035 and $27,271 for 2024, 2023 and 2022, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $16,417 in 2025, $16,334 in 2026, $15,816 in 2027, $15,419 in 2028, and $15,017 in 2029. At December 31, 2024 and 2023, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2024 and 2023. The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included in other in the table above.

EQUITY-METHOD INVESTMENT

EQUITY-METHOD INVESTMENT	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity ("VIE") because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company generally receives up to 2/3 of the production offtake capacity, which (percentage of offtake) may be adjusted from time to time to the extent the owners agree as such, and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $489, $509, and $559 for the years ended December 31, 2024, 2023, and 2022, respectively, relating to its portion of the joint venture’s expenses in other expense. The Company made capital contributions to the investment totaling $269, $290, and $355 for the years ended December 31, 2024, 2023, and 2022 respectively. The carrying value of the joint venture at December 31, 2024 and 2023 was $3,856 and $4,076, respectively, and is recorded in "Other non-current assets" on the consolidated balance sheets.

REVOLVING LOAN

REVOLVING LOAN	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
REVOLVING LOAN	REVOLVING LOAN On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement (the "2022 Credit Agreement") with certain lenders in the form of a senior secured revolving credit facility, due on July 27, 2027. The 2022 Credit Agreement allows for up to $550,000 of borrowing. The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company's discretion. As of December 31, 2024 and 2023, the total balance outstanding on the 2022 Credit Agreement amounted to $190,000 and $309,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. Amounts outstanding under the 2022 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2022 Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2022 Credit Agreement, and the interest rate was 5.438% at December 31, 2024. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2022 Credit Agreement and ranges from 0.150% to 0.225% (0.150% at December 31, 2024). The unused portion of the revolving loan amounted to $360,000 at December 31, 2024. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders. Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the 2022 Credit Agreement. Capitalized costs net of accumulated amortization totaled $743 and $1,030 at December 31, 2024 and 2023, respectively, and are included in "Other non-current assets" on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $287, $287, and $335 for the years ended December 31, 2024, 2023, and 2022, respectively, and are included in "Interest expense" in the accompanying consolidated statements of earnings. The 2022 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At December 31, 2024, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements is secured by assets of the Company.

NET EARNINGS PER COMMON SHARE

NET EARNINGS PER COMMON SHARE	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
NET EARNINGS PER COMMON SHARE	NET EARNINGS PER COMMON SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share: Year Ended December 31, 2024 2023 2022 Net Earnings - Basic and Diluted $ 128,475 $ 108,543 $ 105,367 Share (000s) Weighted Average Common Shares - Basic 32,332 32,108 32,019 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 386 340 374 Weighted Average Common Shares - Diluted 32,718 32,448 32,393 Net Earnings Per Share - Basic $ 3.97 $ 3.38 $ 3.29 Net Earnings Per Share - Diluted $ 3.93 $ 3.35 $ 3.25

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for 2024, 2023 and 2022 was 22.8%, 20.9% , and 21.2%, respectively . The increase from 2023 to 2024 is primarily due to an increase in certain foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences. The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and the Company's specific plans for reinvestment of those subsidiary earnings. In 2023, due to prevailing economic conditions of increased interest rates and subsequent borrowing costs, the Company remitted approximately $18,000 from its Belgium subsidiary and incurred an income tax expense of approximately $20 in the year ended December 31, 2023. The remittance was used to pay down U.S. debt. There was no such remittance during the year ended December 31, 2024. The Company projects that its foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to change its assertion on its remaining undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion. Income tax expense consists of the following: 2024 2023 2022 Current: Federal $ 30,208 $ 27,306 $ 26,423 Foreign 10,376 7,634 7,103 State 4,173 4,403 3,964 Deferred: Federal (2,442) (7,737) (7,532) Foreign (3,192) (2,285) (215) State (1,145) (603) (1,361) Total income tax provision $ 37,978 $ 28,718 $ 28,382 The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2024, 2023, and 2022 to earnings before income tax expense due to the following: 2024 2023 2022 Income tax at Federal statutory rate $ 34,955 $ 28,825 $ 28,087 State income taxes, net of Federal income taxes 2,284 2,513 1,862 Change in foreign tax reserves 2,146 — — Stock options (1,904) (1,004) (676) Foreign-derived intangible income (FDII) (1,562) (1,752) (1,778) Foreign rate differential 1,024 946 2,066 Other 1,035 (810) (1,179) Total income tax provision $ 37,978 $ 28,718 $ 28,382 The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2024 and 2023 were as follows: 2024 2023 Deferred tax assets: Inventories $ 2,437 $ 1,049 Share-based compensation 4,476 5,565 Lease liabilities 4,296 4,812 Research and development 12,838 12,653 Other 5,658 3,874 Total deferred tax assets 29,705 27,953 Deferred tax liabilities: Amortization $ (38,532) $ (42,351) Depreciation (26,234) (28,937) Prepaid expenses (306) (421) Foreign currency and interest rate swaps (642) (647) Right of use assets (4,032) (4,574) Other (3,656) (3,047) Total deferred tax liabilities (73,402) (79,977) Valuation allowance (25) (22) Net deferred tax liability $ (43,722) $ (52,046) As of December 31, 2024, the Company has state income tax net operating loss (NOL) carryforwards of $314. The state NOL carryforwards will expire between 2026 and 2035. The Company believes that the benefit from the state NOL carryforwards will not be realized, therefore, a valuation allowance has been established in the amount of $25. Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows: 2024 2023 2022 Balance at beginning of period $ 4,650 $ 5,815 $ 5,881 Increases for tax positions of prior years 3,211 1,353 2,194 Decreases for tax positions of prior years (1,141) (2,518) (2,260) Balance at end of period $ 6,720 $ 4,650 $ 5,815 All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods. The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2024, 2023 and 2022, these amounts were increased by $939 and reduced by $322, and $371, respectively. As of December 31, 2024 and 2023, accrued interest and penalties were $2,352 and $1,413, respectively. Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2020 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months. The European Union (“EU”) member states formally adopted the EU’s Pillar Two Directive, which was established by the Organization for Economic Co-operation and Development. Pillar Two generally provides for a 15 percent minimum effective tax rate for the jurisdictions where multinational enterprises operate. While the Company does not anticipate that this will have a material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Balchem Corporation reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The reportable segments are organized based on the end use of the products manufactured and sold. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated." Human Nutrition and Health The Human Nutrition and Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products; proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity, and methylsulfonylmethane ("MSM"), which is a widely used nutritional ingredient that helps provide benefits for joint health, sports nutrition, skin and beauty, and healthy aging. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Animal Nutrition and Health The Animal Nutrition and Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. This segment also manufactures MSM, which is a widely used nutritional ingredient that provides benefits for pet health. Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products The Specialty Products segment ("SP") re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. Ethylene oxide is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Contract sterilizers and medical device manufacturers are principal customers for this product. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage, to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes, and for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to. The Company’s performance gases and chemicals are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. The Company also sells single use canisters for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate ® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. The Company's CODM is the Chief Executive Officer. The CODM receives a profit and loss reporting package which provides segment information including revenue, cost of goods sold, gross margin, total operating expenses, and earnings from operations. The CODM utilizes this monthly profit and loss reporting package to analyze segment performance and appropriately allocate resources. Pursuant to ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures", the significant segment information is summarized as follows: For the Year Ended December 31, 2024 HNH ANH SP Other and Unallocated Total Net sales $ 600,258 $ 214,710 $ 132,749 $ 5,967 $ 953,684 Cost of sales 378,411 (1) 171,409 (1) 59,449 (1) 8,209 (1) 617,478 Gross margin 221,847 43,301 73,300 (2,242) 336,206 Operating expenses 85,890 (2) 29,288 (3) 33,394 (4) 4,725 (5) 153,297 Earnings from operations 135,957 14,013 39,906 (6,967) 182,909 Other expenses: Interest expense, net 16,528 Other income (72) 16,456 Earnings before income tax expense 166,453 Income tax expense 37,978 Net earnings $ 128,475 (1) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (2) Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. (3) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. (4) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (5) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs. For the Year Ended December 31, 2023 HNH ANH SP Other and Unallocated Total Net sales $ 550,751 $ 238,326 $ 125,965 $ 7,397 $ 922,439 Cost of sales 366,539 (6) 183,827 (6) 62,183 (6) 7,834 (6) 620,383 Gross margin 184,212 54,499 63,782 (437) 302,056 Operating expenses 81,793 (7) 26,923 (8) 29,203 (9) 4,944 (10) 142,863 Earnings from operations 102,419 27,576 34,579 (5,381) 159,193 Other expenses: Interest expense, net 22,613 Other income (681) 21,932 Earnings before income tax expense 137,261 Income tax expense 28,718 Net earnings $ 108,543 (6) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (7 Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. These expenses were partially offset by favorable adjustments to transaction costs. (8) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. These expenses were partially offset by favorable adjustments to transaction costs. (9) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (10) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs and unallocated amortization expense related to an intangible asset in connection with a company-wide ERP system implementation. For the Year Ended December 31, 2022 HNH ANH SP Other and Unallocated Total Net sales $ 527,131 $ 262,297 $ 131,438 $ 21,492 $ 942,358 Cost of sales 373,063 (11) 200,252 (11) 70,343 (11) 18,249 (11) 661,907 Gross margin 154,068 62,045 61,095 3,243 280,451 Operating expenses 71,943 (12) 25,989 (13) 28,306 (14) 9,027 (15) 135,265 Earnings from operations 82,125 36,056 32,789 (5,784) 145,186 Other expenses: Interest expense, net 10,268 Other expense 1,169 11,437 Earnings before income tax expense 133,749 Income tax expense 28,382 Net earnings $ 105,367 (11) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (12) Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. (13) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. (14) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (15) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs, unallocated legal fees, and unallocated amortization expense related to an intangible asset in connection with a company-wide ERP system implementation. Business Segment Assets 2024 2023 HNH $ 1,185,962 $ 1,180,527 ANH 161,243 166,994 SP 161,283 168,307 Other and Unallocated (16) 66,883 81,383 Total $ 1,575,371 $ 1,597,211 (16) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. Depreciation/Amortization 2024 2023 2022 HNH $ 31,668 $ 38,568 $ 33,728 ANH 8,233 7,876 6,685 SP 7,044 7,278 7,507 Other and Unallocated 1,028 1,213 3,928 Total $ 47,973 $ 54,935 $ 51,848 Capital Expenditures 2024 2023 2022 HNH $ 17,570 $ 26,415 $ 33,668 ANH 13,201 6,993 10,809 SP 4,050 3,535 4,004 Other and Unallocated 327 331 605 Total $ 35,148 $ 37,274 $ 49,086

REVENUE

REVENUE	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: 2024 2023 2022 Product Sales Revenue $ 951,947 $ 919,951 $ 939,166 Royalty Revenue 1,737 2,488 3,192 Total Revenue $ 953,684 $ 922,439 $ 942,358 The following table presents revenues disaggregated by geography, based on customers' delivery addresses: 2024 2023 2022 United States $ 723,300 $ 689,601 $ 682,238 Foreign Countries 230,384 232,838 260,120 Total $ 953,684 $ 922,439 $ 942,358 Product Sales Revenues The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue. Royalty Revenues Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment. Contract Liabilities The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable. The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the year for: 2024 2023 2022 Income taxes $ 42,643 $ 35,725 $ 33,016 Interest $ 17,697 $ 25,933 $ 11,879 Non-cash financing and investing activities: 2024 2023 2022 Dividends payable $ 28,510 $ 25,717 $ 23,129 Contingent consideration liability $ — $ — $ 11,872

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	12 Months Ended
	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME The changes in accumulated other comprehensive income (loss) were as follows: Years Ended December 31, 2024 2023 2022 Net foreign currency translation adjustment $ (32,590) $ 16,809 $ (4,799) Net change of cash flow hedge (see Note 20 for further information) Unrealized (loss) gain on cash flow hedge — (1,406) 3,564 Tax — 341 (868) Net of tax — (1,065) 2,696 Net change in postretirement benefit plan (see Note 15 for further information) Prior service loss (gain) arising during the period 206 132 (41) Amortization of prior service credit — — 9 Amortization of (gain) loss (10) 8 (2) Total before tax 196 140 (34) Tax (44) (39) (24) Net of tax 152 101 (58) Total other comprehensive (loss) income $ (32,438) $ 15,845 $ (2,161) Included in "Net foreign currency translation adjustment" was a loss of $1,455 related to a net investment hedge, net of tax benefits of $471 for the year ended December 31, 2023, and a gain of $3,851 related to a net investment hedge, net of tax expenses of $1,236, for the year ended December 31, 2022. There were no such gains or losses for the year ended December 31, 2024. The Company settled its derivative instruments on their maturity date of June 27, 2023. See Note 20, Derivative Instruments and Hedging Activities . Accumulated other comprehensive loss at December 31, 2024 and 2023 consisted of the following: Foreign currency Cash flow hedge Postretirement benefit plan Total Balance December 31, 2023 $ 8,408 $ — $ 283 $ 8,691 Other comprehensive (loss) income (32,590) — 152 (32,438) Balance December 31, 2024 $ (24,182) $ — $ 435 $ (23,747)

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Defined Contribution Plans The Company sponsors one 401(k) savings plan for eligible employees, which allows participants to make pretax or after tax contributions and the Company matches certain percentages of those contributions. The plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees. In addition, on August 30, 2022, the Company completed the acquisition of Bergstrom, which sponsored one defined contribution plan for its employees. The Bergstrom plan merged into the Company sponsored 401(k) savings plan on January 1, 2023. The Company provided for matching 401(k) savings plan contributions of $4,644, $4,381, and $4,363 in 2024, 2023 and 2022, respectively. There were no profit sharing contributions in 2024. Profit sharing contributions in 2023 and 2022 were not material. Postretirement Medical Plans The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for executive officers of the Company who meet eligibility requirements as set forth in the Company's Officer Retiree Program. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. The actuarial recorded liabilities for such unfunded postretirement benefits are as follows: Change in benefit obligation: 2024 2023 Benefit obligation at beginning of year $ 1,395 $ 1,465 Service cost with interest to end of year 113 108 Interest cost 55 62 Participant contributions 20 23 Benefits paid (32) (30) Actuarial gain (29) (233) Benefit obligation at end of year $ 1,522 $ 1,395 Change in plan assets: 2024 2023 Fair value of plan assets at beginning of year $ — $ — Employer contributions 12 7 Participant contributions 20 23 Benefits paid (32) (30) Fair value of plan assets at end of year $ — $ — Amounts recognized in consolidated balance sheet: 2024 2023 Accumulated postretirement benefit obligation $ (1,522) $ (1,395) Fair value of plan assets — — Funded status (1,522) (1,395) Unrecognized prior service cost — 9 Unrecognized net loss (gain) 8 (2) Net amount recognized in consolidated balance sheet (after ASC 715) (included in $ (1,522) $ (1,395) Accrued postretirement benefit cost (included in "Other long-term obligations") N/A N/A Components of net periodic benefit cost: 2024 2023 2022 Service cost with interest to end of year $ 113 $ 108 $ 79 Interest cost 55 62 26 Amortization of prior service cost — — 9 Amortization of (gain) loss (10) 8 (2) Total net periodic benefit cost $ 158 $ 178 $ 112 Estimated future employer contributions and benefit payments are as follows: Year 2025 $ 121 2026 106 2027 88 2028 95 2029 113 Years 2030-2034 741 Assumptions to determine benefit obligations: 2024 2023 Discount rate 4.85 % 4.15 % Assumptions to determine net cost: 2024 2023 2022 Discount rate 4.15 % 4.40 % 2.10 % Defined Benefit Pension Plans The Company contributes to one multi-employer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability. The Company’s participation in this plan for the annual period ended December 31, 2024 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2024 and 2023 was affected by a 4.0% increase in the 2024 contribution rate. There have been no other significant changes that affect the comparability of 2024 and 2023 contributions. The Company does not represent more than 5% of the contributions to this pension fund. Pension EIN/Pension Pension Plan Protection Act Zone Status FIP/RP Status Contributions of Balchem Corporation Surcharge Expiration Date of Collective- 2024 2023 2024 2023 2022 Central States, 36-6044243 Critical as of 1/1/24 Critical as of 1/1/23 Implemented $1,073 $1,020 $939 No 7/12/2025 The Company provides an unfunded defined benefit pension plan for employees working in Belgium. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows: Change in benefit obligation: 2024 2023 Benefit obligation at beginning of year $ 1,660 $ 1,589 Service cost with interest to end of year 72 65 Interest cost 54 65 Benefits paid (42) (188) Actuarial loss 488 80 Exchange rate changes (98) 49 Benefit obligation at end of year $ 2,134 $ 1,660 Change in plan assets: 2024 2023 Fair value of plan assets at beginning of year $ 1,240 $ 1,196 Actual return on plan assets 216 56 Employer contributions 181 138 Benefits paid (42) (188) Exchange rate changes (74) 38 Fair value of plan assets at end of year $ 1,521 $ 1,240 Amounts recognized in consolidated balance sheet: 2024 2023 Benefit obligation $ (2,134) $ (1,660) Fair value of plan assets 1,521 1,240 Funded status (613) (420) Unrecognized prior service cost N/A N/A Unrecognized net (gain)/loss N/A N/A Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) $ (613) $ (420) Accrued postretirement benefit cost (included in other long-term obligations) N/A N/A Components of net periodic benefit cost: 2024 2023 2022 Service cost with interest to end of year $ 72 $ 65 $ 44 Interest cost 54 65 17 Expected return on plan assets (40) (42) (37) Total net periodic benefit cost $ 86 $ 88 $ 24 Estimated future benefit payments are as follows: Year 2025 $ 1 2026 1 2027 1 2028 1 2029 1 Years 2030-2034 1,353 Assumptions to determine benefit obligations: 2024 2023 Discount rate 3.35 % 3.45 % Assumptions to determine net cost: 2024 2023 2022 Discount rate 3.45 % 4.00 % 1.00 % Expected return on assets 3.25 % 3.25 % 3.25 % Deferred Compensation Plan The Company maintains an unfunded, non-qualified deferred compensation plan for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability was $11,470 as of December 31, 2024, of which $11,449 was included in "Other long-term obligations" and $21 was included in "Accrued compensation and other benefits" on the Company's consolidated balance sheets. The deferred compensation liability was $10,188 as of December 31, 2023 and was included in "Other long-term obligations" on the Company’s consolidated balance sheets. The related assets of the irrevocable trust funds (also known as "rabbi trust funds") were $11,465 and $10,188 as of December 31, 2024 and 2023, respectively, and were included in "Other non-current assets" on the Company's consolidated balance sheets.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is obligated to make rental payments under non-cancelable operating and finance leases. Aggregate future minimum rental payments required under these leases at December 31, 2024 are disclosed in Note 19, Leases . The Company’s Verona, Missouri facility, while held by a prior owner, Syntex Agribusiness, Inc. (“Syntex”), was designated by the U.S. Environmental Protection Agency (the "EPA") as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by Syntex under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. One of the sellers, in turn, has the benefit of certain contractual indemnification by Syntex in relation to the implementation of the above-described Superfund remedy. In June 2023, in response to a Special Notice Letter received from the EPA in 2022, BCP Ingredients, Inc. ("BCP"), the Company's subsidiary that operates the site, Syntex, EPA, and the State of Missouri entered into an Administrative Settlement Agreement and Order on Consent (“ASAOC”) for a focused remedial investigation/feasibility study ("RI/FS") under which (a) BCP will conduct a source investigation of potential source(s) of releases of 1,4-dioxane and chlorobenzene at a portion of the site and (b) BCP and Syntex will complete a RI/FS to determine a potential remedy, if any is required. Activities under the ASAOC are underway and are expected to continue for some period of time. Separately, in June 2022, the EPA conducted an inspection of BCP’s Verona, Missouri facility (“2022 EPA Inspection”) which was followed by BCP entering into an Administrative Order for Compliance on Consent (“AOC”) with the EPA in relation to its risk management program at the Verona facility. Further, in January 2023, BCP entered into an Amended AOC with the EPA whereby the parties agreed to the extension of certain timelines. BCP timely completed all requirements under the Amended AOC. In November 2023, BCP received a notice from the Environment and Natural Resources Division of the U.S Department of Justice (“DOJ”) primarily related to the 2022 EPA Inspection, which extended the opportunity to discuss alleged violations of Sections 112(r)(7) of the Clean Air Act and regulations in 40 C.F.R. Part 68, commonly known as the Risk Management Plan Rule (“RMP Rule”). BCP participated in such discussions during 2024, and in December 2024, BCP reached a settlement with the EPA and DOJ to resolve these alleged violations. Pursuant to the settlement, which was entered into on January 31, 2025, BCP agreed to: (a) pay a $300 civil penalty; (b) invest in a new scrubber system; and (c) spend $350 to implement projects benefiting the surrounding community, such as emergency equipment for the local fire department and two vehicles to be used as mobile health clinics. The amount associated with this settlement was consistent with the amount previously accrued as a loss contingency. In addition to the above, from time to time, the Company is a party to various legal proceedings, litigation, claims and assessments. While it is not possible to predict the ultimate disposition of each of these matters, management believes that the ultimate outcome of such matters will not have a material effect on the Company's consolidated financial position, results of operations, liquidity or cash flows.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2024 and 2023 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2024 and 2023 included $1,040 and $959 in money market funds and other interest-bearing deposit accounts, respectively. Non-current assets at December 31, 2024 and 2023 included $11,465 and $10,188, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties. As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2024. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2024: (1) 1-2 years, 6.76%-6.25% (2) 3-4 years, 7.35%-6.84% (3) 5-9 years, 7.69%-7.18% and (4) 10+ years, 8.41%-7.90%. Right of use assets and lease liabilities at December 31, 2024 and 2023 are summarized as follows: Right of use assets 2024 2023 Operating leases $ 15,320 $ 17,763 Finance lease 1,730 2,101 Total $ 17,050 $ 19,864 Lease liabilities - current 2024 2023 Operating leases $ 3,134 $ 3,949 Finance lease 194 272 Total $ 3,328 $ 4,221 Lease liabilities - non-current 2024 2023 Operating leases $ 12,967 $ 14,601 Finance lease 1,749 1,943 Total $ 14,716 $ 16,544 For the years ended December 31, 2024, 2023, and 2022, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions: Year ended December 31, 2024 2023 2022 Lease Cost Operating lease cost $ 5,456 $ 5,307 $ 4,478 Finance Lease cost Amortization of ROU asset 232 242 210 Interest on lease liabilities 105 115 125 Total finance lease 337 357 335 Total lease cost $ 5,793 $ 5,664 $ 4,813 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 5,454 $ 4,757 $ 4,269 Operating cash flows from finance leases 105 115 125 Financing cash flows from finance leases 216 222 177 $ 5,775 $ 5,094 $ 4,571 ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals $ 1,669 $ 6,365 $ 11,488 Weighted-average remaining lease term - operating leases 9.03 years 9.33 years 5.63 years Weighted-average remaining lease term - finance leases 8.37 years 9.07 years 9.95 years Weighted-average discount rate - operating leases 7.6 % 7.4 % 2.7 % Weighted-average discount rate - finance leases 5.1 % 5.0 % 5.0 % Rent expense charged to operations under operating lease agreements for 2024, 2023, and 2022 aggregated approximately $5,456, $5,307, and $4,478, respectively. Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2024 are as follows: Year 2025 $ 5,008 2026 4,399 2027 3,155 2028 2,393 2029 1,937 Thereafter 5,819 Total minimum lease payments $ 22,711
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2024. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2024: (1) 1-2 years, 6.76%-6.25% (2) 3-4 years, 7.35%-6.84% (3) 5-9 years, 7.69%-7.18% and (4) 10+ years, 8.41%-7.90%. Right of use assets and lease liabilities at December 31, 2024 and 2023 are summarized as follows: Right of use assets 2024 2023 Operating leases $ 15,320 $ 17,763 Finance lease 1,730 2,101 Total $ 17,050 $ 19,864 Lease liabilities - current 2024 2023 Operating leases $ 3,134 $ 3,949 Finance lease 194 272 Total $ 3,328 $ 4,221 Lease liabilities - non-current 2024 2023 Operating leases $ 12,967 $ 14,601 Finance lease 1,749 1,943 Total $ 14,716 $ 16,544 For the years ended December 31, 2024, 2023, and 2022, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions: Year ended December 31, 2024 2023 2022 Lease Cost Operating lease cost $ 5,456 $ 5,307 $ 4,478 Finance Lease cost Amortization of ROU asset 232 242 210 Interest on lease liabilities 105 115 125 Total finance lease 337 357 335 Total lease cost $ 5,793 $ 5,664 $ 4,813 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 5,454 $ 4,757 $ 4,269 Operating cash flows from finance leases 105 115 125 Financing cash flows from finance leases 216 222 177 $ 5,775 $ 5,094 $ 4,571 ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals $ 1,669 $ 6,365 $ 11,488 Weighted-average remaining lease term - operating leases 9.03 years 9.33 years 5.63 years Weighted-average remaining lease term - finance leases 8.37 years 9.07 years 9.95 years Weighted-average discount rate - operating leases 7.6 % 7.4 % 2.7 % Weighted-average discount rate - finance leases 5.1 % 5.0 % 5.0 % Rent expense charged to operations under operating lease agreements for 2024, 2023, and 2022 aggregated approximately $5,456, $5,307, and $4,478, respectively. Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2024 are as follows: Year 2025 $ 5,008 2026 4,399 2027 3,155 2028 2,393 2029 1,937 Thereafter 5,819 Total minimum lease payments $ 22,711

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023, which was designated as cash flow hedge. The net interest income related to the interest rate swap contract was $1,518 and $400 for the years ended December 31, 2023 and 2022, respectively. There was no such income or expense during the year ended December 31, 2024 as the interest rate swap was settled on its maturity date of June 27, 2023. The net interest income and expense were recorded in the consolidated statements of earnings under "Interest expense, net." On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas, which was designated as net investment hedge. The derivative had a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $1,119 and $2,250 for the years ended December 31, 2023 and 2022, respectively. There was no such income or expense during the year ended December 31, 2024 as the cross-currency swap was settled on its maturity date of June 27, 2023. The interest income was recorded in the consolidated statements of earnings under "Interest expense, net." The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2024. The proceeds from the settlement of the cross-currency swap in the amount of $2,740 were classified as investing activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2023. There were no gains and losses on hedging instruments recognized in accumulated other comprehensive income (loss) for the year ended December 31, 2024 as the derivative instruments settled on their maturity date of June 27, 2023. Gains and losses on our hedging instruments for the years ended December 31, 2023, and 2022 were recognized in accumulated other comprehensive income (loss) and categorized as follows: Location within Statements of Comprehensive Income 2023 2022 Cash flow hedge (interest rate swap), net of tax Unrealized (loss) gain on cash flow hedge, net $ (1,065) $ 2,696 Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment (1,455) 3,851 $ (2,520) $ 6,547 In connection with the Kappa acquisition (see Note 2, Significant Acquisitions

QUARTERLY FINANCIAL INFORMATION

QUARTERLY FINANCIAL INFORMATION (UNAUDITED)	12 Months Ended
	Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY FINANCIAL INFORMATION (UNAUDITED)	QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (In thousands, except per share data) 2024 2023 First Second Third Fourth First Second Third Fourth Net sales $ 239,659 $ 234,081 $ 239,940 $ 240,004 $ 232,540 $ 231,252 $ 229,948 $ 228,699 Gross margin 81,514 82,994 85,361 86,337 73,170 77,349 76,544 74,993 Earnings before income taxes 36,850 41,226 43,893 44,484 29,119 38,400 36,475 33,267 Net earnings 28,986 32,069 33,837 33,583 22,710 30,110 29,075 26,648 Basic net earnings per common share $ 0.90 $ 0.99 $ 1.05 $ 1.05 $ 0.71 $ 0.94 $ 0.91 $ 0.83 Diluted net earnings per common share $ 0.89 $ 0.98 $ 1.03 $ 1.03 $ 0.70 $ 0.93 $ 0.90 $ 0.82

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	Allowance Inventory Balance - December 31, 2021 $ 928 $ 1,425 Additions charged to costs and expenses 401 6,786 Adjustments/deductions (a) (103) (5,571) Balance - December 31, 2022 1,226 2,640 Additions charged to costs and expenses 37 2,450 Adjustments/deductions (a) (355) (2,627) Balance - December 31, 2023 908 2,463 Additions charged to costs and expenses 299 4,123 Adjustments/deductions (a) (298) (2,379) Balance - December 31, 2024 $ 909 $ 4,207 (a) Represents write-offs and other adjustments

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net earnings	$ 33,583	$ 33,837	$ 32,069	$ 28,986	$ 26,648	$ 29,075	$ 30,110	$ 22,710	$ 128,475	$ 108,543	$ 105,367

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity is a critical part of our enterprise risk management. The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity. To more effectively address cybersecurity threats, we have numerous security layers within our least privilege network approach which is managed by our Information Technology ("IT") department. Our cybersecurity programs align with numerous standards and continues to grow and develop as new technologies emerge. Further, we have regular user awareness testing and trainings in place which helps keep all end users and executive leadership up-to-date on the most current threats. The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance. Additional activities to maintain and enhance information security are discussed below. • Reliable, Scalable Systems and Infrastructure Our information security systems, infrastructure, and processes are built on and follow the U.S. National Institute of Standards and Technology ("NIST") framework for information security, which is a set of guidelines, accepted standards, and best practices for mitigating organization cybersecurity risks published by NIST. We continue to make significant investments in industry-leading and advanced technologies as part of our strategy to strengthen our security posture, business continuity capabilities, and ability to protect and safeguard systems and stakeholder data. Our Information Security Program and systems are tested and assessed annually by an independent third party. • Automation and Artificial Intelligence We have implemented automated systems to proactively test attack vectors by emulating inside and outside threats resulting in the validation of our ability to detect and defend against a cyber attack. Artificial intelligence is used as part of early warning systems designed to detect, alert, and respond to potential cyber threats. • Training Recognizing that information security, stakeholder data, and privacy principles involve more than just systems and infrastructure, we provide semi-annual cybersecurity education and training to all users with access to IT systems, devices, or applications. Internal social engineering phishing campaigns are conducted regularly with the goal of building a culture of cybersecurity, as well as raising awareness and reinforcing best practices across the organization. Third parties also play a role in our cybersecurity. We engage third-party services to conduct evaluations of our security controls, whether through penetration testing, independent audits or consulting on best practices to address new challenges. These evaluations include testing both the design and operational effectiveness of security controls. We apply a risk-based approach to mitigate cybersecurity risks associated with our use of third-party service providers and cybersecurity considerations affect the selection and oversight of these third-party service providers. We perform due diligence on third parties that have access to our most critical systems, data or facilities that house such systems or data. While we have experienced cybersecurity threats in the past in the normal course of business and expect to continue to experience such threats from time to time, to date, none have had a material adverse effect on our business, financial condition, results of operations or cash flows. Even with the extensive approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us. See Item 1A. “Risk Factors - Operational Risks - Disruptions or breaches of our information systems could adversely affect us” for a discussion of cybersecurity risks. In the event of a possible cybersecurity incident, we would immediately implement our crisis management plan, which includes the following steps: (1) Internal reporting and review of the incident or development (2) Gathering and assessing information (3) Developing and implementing a communications strategy (4) Monitoring and evaluating a response (5) Debrief and recovery
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Cybersecurity is a critical part of our enterprise risk management. The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity. To more effectively address cybersecurity threats, we have numerous security layers within our least privilege network approach which is managed by our Information Technology ("IT") department. Our cybersecurity programs align with numerous standards and continues to grow and develop as new technologies emerge. Further, we have regular user awareness testing and trainings in place which helps keep all end users and executive leadership up-to-date on the most current threats. The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity. To more effectively address cybersecurity threats, we have numerous security layers within our least privilege network approach which is managed by our Information Technology ("IT") department.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance.
Cybersecurity Risk Role of Management [Text Block]	The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance. Additional activities to maintain and enhance information security are discussed below. • Reliable, Scalable Systems and Infrastructure Our information security systems, infrastructure, and processes are built on and follow the U.S. National Institute of Standards and Technology ("NIST") framework for information security, which is a set of guidelines, accepted standards, and best practices for mitigating organization cybersecurity risks published by NIST. We continue to make significant investments in industry-leading and advanced technologies as part of our strategy to strengthen our security posture, business continuity capabilities, and ability to protect and safeguard systems and stakeholder data. Our Information Security Program and systems are tested and assessed annually by an independent third party. • Automation and Artificial Intelligence We have implemented automated systems to proactively test attack vectors by emulating inside and outside threats resulting in the validation of our ability to detect and defend against a cyber attack. Artificial intelligence is used as part of early warning systems designed to detect, alert, and respond to potential cyber threats. • Training Recognizing that information security, stakeholder data, and privacy principles involve more than just systems and infrastructure, we provide semi-annual cybersecurity education and training to all users with access to IT systems, devices, or applications. Internal social engineering phishing campaigns are conducted regularly with the goal of building a culture of cybersecurity, as well as raising awareness and reinforcing best practices across the organization.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity. To more effectively address cybersecurity threats, we have numerous security layers within our least privilege network approach which is managed by our Information Technology ("IT") department. Our cybersecurity programs align with numerous standards and continues to grow and develop as new technologies emerge. Further, we have regular user awareness testing and trainings in place which helps keep all end users and executive leadership up-to-date on the most current threats. The global head of our IT department has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. He has degrees in both management information systems and cybersecurity - and has held a number of progressing roles, including management of global infrastructure, information security and technology operations at Balchem, in addition to managing a global team of information technology and cybersecurity experts. The IT department provides regular updates to senior management. Additionally, he provides at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

BUSINESS DESCRIPTION AND SUMM_2

BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Revenue Recognition and Cost of Sales	Revenue Recognition Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer. In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers , revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer. Cost of Sales Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable
Inventories	Inventories Inventories are valued at the lower of cost (first in, first out) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 years Equipment 2-28 years Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations	Business Concentrations
Post-employment Benefits	Post-employment Benefits We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease. In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets	Goodwill and Acquired Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired in accordance with ASC 805, "Business Combinations". Goodwill and intangible assets acquired in a business combination that have indefinite useful lives are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the assets might be impaired, in accordance with the provisions of ASC 350, "Intangibles-Goodwill and Other". The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the assets might be impaired. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. In accordance with this update, a goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. As of October 1, 2024 and 2023, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, certain components of the discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2024 and 2023. The Company may resume performing the qualitative assessment in subsequent periods. The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 - 20 Trademarks and trade names 2 - 17 Developed technology 5 - 12 Regulatory registration costs 5 - 10 Patents and trade secrets 15 - 17 Other 2 - 18
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained. Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates	Use of Estimates Management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments. In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
Research and Development	Research and Development Research and development costs are associated directly with the Company's efforts to develop, design, and enhance its products, services, technologies, or processes. Such costs are expensed as incurred.
Net Earnings Per Common Share	Net Earnings Per Common Share Basic net earnings per common share is calculated by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation	Stock-based Compensation The Company has stock-based employee compensation plans, which are described more fully in Note 3, Stockholders' Equity . The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the statement of earnings as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets	Impairment of Long-lived Assets
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments was to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes. The derivative instruments were with the above single counterparty and were subject to a contractual agreement that provided for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments were categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet. The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2024 and 2023. On a quarterly basis through their maturity, we assessed the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. The hedging relationships were determined to be highly effective. As such, the net change in fair values of the interest rate swap, that qualified as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and subsequently reclassified into interest expense as interest payments were made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remain in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, Derivative Instruments and Hedging Activities , for detailed information about our derivative financial instruments.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40)." The new guidance is intended to enhance transparency and disclosures by requiring public entities to provide disaggregated disclosures of certain categories of expenses on an annual and interim basis. The ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on the consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment in this Update should be applied on a prospective basis, with retrospective application permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on the consolidated financial statements and related disclosures. Recently Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures." The ASU expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning December 15, 2024. The Company adopted this accounting guidance on December 31, 2024, and applied it retrospectively to all prior periods presented in our consolidated financial statements. Refer to Note 11, Segment Information for the expanded disclosures. In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", and in December 2022 subsequently issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” These ASU’s provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The Standards Updates provide optional expedients and exceptions for applying accounting principles generally accepted in the United States to contract modifications and hedging relationships that reference LIBOR or another reference rate that are expected to be discontinued. The Standards Updates were effective upon issuance and can generally be applied through December 31, 2024. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its interest rate swap and replaced LIBOR with 1-month CME Term SOFR. The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. The interest rate swap matured on June 27, 2023.

BUSINESS DESCRIPTION AND SUMM_3

BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of Plant and Equipment Estimated Useful Lives	Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 years Equipment 2-28 years Property, plant and equipment at December 31, 2024 and 2023 are summarized as follows: 2024 2023 Land $ 11,690 $ 11,787 Building 106,954 104,363 Equipment 315,001 312,704 Construction in progress 77,508 59,981 511,153 488,835 Less: Accumulated depreciation 228,999 212,796 Property, plant and equipment, net $ 282,154 $ 276,039
Schedule of Intangible Assets Estimated Useful Lives	The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 - 20 Trademarks and trade names 2 - 17 Developed technology 5 - 12 Regulatory registration costs 5 - 10 Patents and trade secrets 15 - 17 Other 2 - 18 As of December 31, 2024 and 2023, the Company had identifiable intangible assets as follows: 2024 2023 Amortization Gross Accumulated Gross Accumulated Customer relationships and lists 10-20 $ 354,051 $ 221,567 $ 362,032 $ 209,651 Trademarks and trade names 2-17 50,971 41,417 50,286 37,773 Developed technology 5-12 40,074 20,362 41,184 17,516 Other 2-18 25,154 21,854 25,733 23,083 $ 470,250 $ 305,200 $ 479,235 $ 288,023

SIGNIFICANT ACQUISITIONS (Table

SIGNIFICANT ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed: Cash and cash equivalents $ 773 Accounts receivable 4,699 Inventories 3,972 Property, plant and equipment 2,243 Right of use assets 866 Customer relationships 29,900 Developed technology 4,600 Trademarks 2,300 Other assets 197 Accounts payable (699) Bank debt (206) Lease liabilities (871) Other liabilities (462) Goodwill 31,550 Total consideration on acquisition date and working capital adjustment 78,862 Net decrease to contingent consideration liability and other post-closing payments (6,916) Total consideration 71,946 To pay off bank debt 206 Total payments $ 72,152 The following table summarizes the fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022. Cash and cash equivalents $ 6,365 Accounts receivable 8,036 Inventories 17,600 Property, plant and equipment 9,854 Right of use assets 3,349 Customer relationships 88,813 Developed technology 15,643 Trademarks 5,046 Other assets 2,399 Accounts payable (3,301) Bank debt (30,648) Lease liabilities (3,349) Other liabilities (4,461) Deferred income taxes, net (24,716) Goodwill 216,383 Total consideration on acquisition date 307,013 Decrease to contingent consideration liability (4,037) Net gain on foreign currency exchange forward contracts (512) Total consideration 302,464 Kappa bank debt paid on acquisition date 30,648 Total payments $ 333,112
Schedule of Pro Forma Information	The following selected unaudited pro forma information presents the consolidated results of operations as if the business combinations in 2022 had occurred as of January 1, 2021. Twelve Months ended December 31, Net Sales Net Earnings Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023 $ 59,532 $ 5,487 Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2022 $ 22,158 $ (5,359) 2023 Supplemental pro forma combined financial $ 922,439 $ 116,317 2022 Supplemental pro forma combined financial $ 982,021 $ 110,181 2021 Supplemental pro forma combined financial $ 859,252 $ 90,672

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost on Net Earnings	The Company’s results for the years ended December 31, 2024, 2023 and 2022 reflected the following compensation cost and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the 2024 2023 2022 Cost of sales $ 1,716 $ 1,900 $ 1,302 Operating expenses 14,960 14,152 11,922 Net earnings (12,865) (12,375) (10,214)
Schedule of Assumptions Used in the Valuation of Option Awards	Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life. Year Ended December 31, Weighted Average Assumptions: 2024 2023 2022 Expected Volatility 28.4 % 28.1 % 30.3 % Expected Term (in years) 5.0 4.8 7.3 Risk-Free Interest Rate 4.1 % 3.9 % 2.8 % Dividend Yield 0.6 % 0.5 % 0.5 %
Summary of Stock Option Activity	A summary of stock option plan activity for 2024, 2023, and 2022 for all plans is as follows: 2024 2023 2022 # of Weighted Average # of Weighted Average # of Weighted Average Outstanding at beginning of year 1,078 $ 104.38 1,045 $ 99.82 867 $ 88.19 Granted 113 143.43 109 138.09 239 139.04 Exercised (221) 77.81 (64) 81.98 (44) 73.58 Forfeited (8) 139.64 (11) 131.79 (17) 124.89 Cancelled — — (1) 138.07 — — Outstanding at end of year 962 $ 114.81 1,078 $ 104.38 1,045 $ 99.82 Exercisable at end of year 603 $ 99.59 720 $ 88.49 654 $ 81.95
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to option activity during the years ended December 31, 2024, 2023 and 2022 is as follows: Years Ended December 31, 2024 2023 2022 Weighted-average fair value of options granted $ 44.52 $ 40.91 $ 44.77 Total intrinsic value of stock options exercised ($000s) $ 18,631 $ 3,241 $ 2,713
Schedule of Additional Information Relating to Stock Options Outstanding	Additional information related to stock options outstanding under all plans at December 31, 2024 is as follows: Options Outstanding Options Exercisable Range of Exercise Shares Weighted Weighted Number Weighted $58.52 - $85.33 222 3.1 $ 76.14 222 $ 76.14 $85.40 - $118.60 212 4.0 101.92 212 101.92 $118.96 - $150.85 528 7.6 136.24 169 127.47 962 5.8 $ 114.81 603 $ 99.59
Schedule of Non-vested Restricted Stock Activity	Non-vested restricted stock activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Shares (000s) Weighted Shares (000s) Weighted Shares (000s) Weighted Non-vested balance at beginning of year 116 $ 133.06 122 $ 124.42 166 $ 99.70 Granted 51 147.98 40 137.20 46 137.17 Vested (39) 124.63 (42) 112.30 (82) 82.15 Forfeited (6) 140.70 (4) 128.06 (8) 118.07 Non-vested balance at end of year 122 $ 141.62 116 $ 133.06 122 $ 124.42
Schedule of Non-vested Performance Share Activity	Non-vested performance share activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Shares (000s) Weighted Shares (000s) Weighted Shares (000s) Weighted Non-vested balance at beginning of year 76 $ 135.25 70 $ 127.69 69 $ 110.72 Granted 47 152.28 42 139.66 39 114.22 Vested (44) 106.57 (36) 98.84 (35) 53.17 Forfeited — — — — (3) 84.09 Non-vested balance at end of year 79 $ 150.73 76 $ 135.25 70 $ 127.69

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories, net of reserves at December 31, 2024 and 2023 consisted of the following: 2024 2023 Raw materials $ 45,319 $ 39,517 Work in progress 4,510 3,960 Finished goods 80,973 66,044 Total inventories $ 130,802 $ 109,521

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 years Equipment 2-28 years Property, plant and equipment at December 31, 2024 and 2023 are summarized as follows: 2024 2023 Land $ 11,690 $ 11,787 Building 106,954 104,363 Equipment 315,001 312,704 Construction in progress 77,508 59,981 511,153 488,835 Less: Accumulated depreciation 228,999 212,796 Property, plant and equipment, net $ 282,154 $ 276,039
Schedule of Long-Lived Assets by Geographical Area	Geographic Area Data - Long-Lived Assets (excluding intangible assets): 2024 2023 United States $ 204,397 $ 203,692 Foreign Countries 77,757 72,347 Total $ 282,154 $ 276,039

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill at December 31, 2022 $ 769,509 Goodwill as a result of an acquisition 341 Impact due to change in foreign exchange rates 9,057 Goodwill at December 31, 2023 778,907 Goodwill as a result of an acquisition 19,376 Impact due to change in foreign exchange rates (18,253) Goodwill at December 31, 2024 $ 780,030 December 31, 2024 December 31, 2023 HNH $ 678,275 $ 673,207 ANH 23,974 24,469 Specialty Products 77,732 81,175 Other and Unallocated 49 56 Total $ 780,030 $ 778,907
Schedule of Identifiable Intangible Assets	The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 - 20 Trademarks and trade names 2 - 17 Developed technology 5 - 12 Regulatory registration costs 5 - 10 Patents and trade secrets 15 - 17 Other 2 - 18 As of December 31, 2024 and 2023, the Company had identifiable intangible assets as follows: 2024 2023 Amortization Gross Accumulated Gross Accumulated Customer relationships and lists 10-20 $ 354,051 $ 221,567 $ 362,032 $ 209,651 Trademarks and trade names 2-17 50,971 41,417 50,286 37,773 Developed technology 5-12 40,074 20,362 41,184 17,516 Other 2-18 25,154 21,854 25,733 23,083 $ 470,250 $ 305,200 $ 479,235 $ 288,023

NET EARNINGS PER COMMON SHARE (

NET EARNINGS PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share: Year Ended December 31, 2024 2023 2022 Net Earnings - Basic and Diluted $ 128,475 $ 108,543 $ 105,367 Share (000s) Weighted Average Common Shares - Basic 32,332 32,108 32,019 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 386 340 374 Weighted Average Common Shares - Diluted 32,718 32,448 32,393 Net Earnings Per Share - Basic $ 3.97 $ 3.38 $ 3.29 Net Earnings Per Share - Diluted $ 3.93 $ 3.35 $ 3.25

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Income Tax Expense	Income tax expense consists of the following: 2024 2023 2022 Current: Federal $ 30,208 $ 27,306 $ 26,423 Foreign 10,376 7,634 7,103 State 4,173 4,403 3,964 Deferred: Federal (2,442) (7,737) (7,532) Foreign (3,192) (2,285) (215) State (1,145) (603) (1,361) Total income tax provision $ 37,978 $ 28,718 $ 28,382
Schedule of Income Tax Reconciliation	The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2024, 2023, and 2022 to earnings before income tax expense due to the following: 2024 2023 2022 Income tax at Federal statutory rate $ 34,955 $ 28,825 $ 28,087 State income taxes, net of Federal income taxes 2,284 2,513 1,862 Change in foreign tax reserves 2,146 — — Stock options (1,904) (1,004) (676) Foreign-derived intangible income (FDII) (1,562) (1,752) (1,778) Foreign rate differential 1,024 946 2,066 Other 1,035 (810) (1,179) Total income tax provision $ 37,978 $ 28,718 $ 28,382
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2024 and 2023 were as follows: 2024 2023 Deferred tax assets: Inventories $ 2,437 $ 1,049 Share-based compensation 4,476 5,565 Lease liabilities 4,296 4,812 Research and development 12,838 12,653 Other 5,658 3,874 Total deferred tax assets 29,705 27,953 Deferred tax liabilities: Amortization $ (38,532) $ (42,351) Depreciation (26,234) (28,937) Prepaid expenses (306) (421) Foreign currency and interest rate swaps (642) (647) Right of use assets (4,032) (4,574) Other (3,656) (3,047) Total deferred tax liabilities (73,402) (79,977) Valuation allowance (25) (22) Net deferred tax liability $ (43,722) $ (52,046)
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows: 2024 2023 2022 Balance at beginning of period $ 4,650 $ 5,815 $ 5,881 Increases for tax positions of prior years 3,211 1,353 2,194 Decreases for tax positions of prior years (1,141) (2,518) (2,260) Balance at end of period $ 6,720 $ 4,650 $ 5,815

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The Company's CODM is the Chief Executive Officer. The CODM receives a profit and loss reporting package which provides segment information including revenue, cost of goods sold, gross margin, total operating expenses, and earnings from operations. The CODM utilizes this monthly profit and loss reporting package to analyze segment performance and appropriately allocate resources. Pursuant to ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures", the significant segment information is summarized as follows: For the Year Ended December 31, 2024 HNH ANH SP Other and Unallocated Total Net sales $ 600,258 $ 214,710 $ 132,749 $ 5,967 $ 953,684 Cost of sales 378,411 (1) 171,409 (1) 59,449 (1) 8,209 (1) 617,478 Gross margin 221,847 43,301 73,300 (2,242) 336,206 Operating expenses 85,890 (2) 29,288 (3) 33,394 (4) 4,725 (5) 153,297 Earnings from operations 135,957 14,013 39,906 (6,967) 182,909 Other expenses: Interest expense, net 16,528 Other income (72) 16,456 Earnings before income tax expense 166,453 Income tax expense 37,978 Net earnings $ 128,475 (1) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (2) Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. (3) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. (4) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (5) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs. For the Year Ended December 31, 2023 HNH ANH SP Other and Unallocated Total Net sales $ 550,751 $ 238,326 $ 125,965 $ 7,397 $ 922,439 Cost of sales 366,539 (6) 183,827 (6) 62,183 (6) 7,834 (6) 620,383 Gross margin 184,212 54,499 63,782 (437) 302,056 Operating expenses 81,793 (7) 26,923 (8) 29,203 (9) 4,944 (10) 142,863 Earnings from operations 102,419 27,576 34,579 (5,381) 159,193 Other expenses: Interest expense, net 22,613 Other income (681) 21,932 Earnings before income tax expense 137,261 Income tax expense 28,718 Net earnings $ 108,543 (6) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (7 Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. These expenses were partially offset by favorable adjustments to transaction costs. (8) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. These expenses were partially offset by favorable adjustments to transaction costs. (9) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (10) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs and unallocated amortization expense related to an intangible asset in connection with a company-wide ERP system implementation. For the Year Ended December 31, 2022 HNH ANH SP Other and Unallocated Total Net sales $ 527,131 $ 262,297 $ 131,438 $ 21,492 $ 942,358 Cost of sales 373,063 (11) 200,252 (11) 70,343 (11) 18,249 (11) 661,907 Gross margin 154,068 62,045 61,095 3,243 280,451 Operating expenses 71,943 (12) 25,989 (13) 28,306 (14) 9,027 (15) 135,265 Earnings from operations 82,125 36,056 32,789 (5,784) 145,186 Other expenses: Interest expense, net 10,268 Other expense 1,169 11,437 Earnings before income tax expense 133,749 Income tax expense 28,382 Net earnings $ 105,367 (11) Cost of sales are primarily comprised of raw materials consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. (12) Operating expenses w ithin HNH are primarily comprised of compensation-related costs, professional services, including advertising and marketing costs, and amortization expense in connection with certain acquired intangible assets. (13) Operating expenses within ANH are primarily comprised of compensation-related costs and professional services, including advertising and marketing costs. (14) Operating expenses within SP are primarily comprised of compensation-related costs, professional services, and amortization expense in connection with certain acquired intangible assets. (15) Operating expenses within Other and Unallocated are primarily comprised of transaction and integration costs, unallocated legal fees, and unallocated amortization expense related to an intangible asset in connection with a company-wide ERP system implementation. Business Segment Assets 2024 2023 HNH $ 1,185,962 $ 1,180,527 ANH 161,243 166,994 SP 161,283 168,307 Other and Unallocated (16) 66,883 81,383 Total $ 1,575,371 $ 1,597,211 (16) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. Depreciation/Amortization 2024 2023 2022 HNH $ 31,668 $ 38,568 $ 33,728 ANH 8,233 7,876 6,685 SP 7,044 7,278 7,507 Other and Unallocated 1,028 1,213 3,928 Total $ 47,973 $ 54,935 $ 51,848 Capital Expenditures 2024 2023 2022 HNH $ 17,570 $ 26,415 $ 33,668 ANH 13,201 6,993 10,809 SP 4,050 3,535 4,004 Other and Unallocated 327 331 605 Total $ 35,148 $ 37,274 $ 49,086

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by Source and Geography	The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: 2024 2023 2022 Product Sales Revenue $ 951,947 $ 919,951 $ 939,166 Royalty Revenue 1,737 2,488 3,192 Total Revenue $ 953,684 $ 922,439 $ 942,358 The following table presents revenues disaggregated by geography, based on customers' delivery addresses: 2024 2023 2022 United States $ 723,300 $ 689,601 $ 682,238 Foreign Countries 230,384 232,838 260,120 Total $ 953,684 $ 922,439 $ 942,358

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Cash paid during the year for: 2024 2023 2022 Income taxes $ 42,643 $ 35,725 $ 33,016 Interest $ 17,697 $ 25,933 $ 11,879 Non-cash financing and investing activities: 2024 2023 2022 Dividends payable $ 28,510 $ 25,717 $ 23,129 Contingent consideration liability $ — $ — $ 11,872

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	12 Months Ended
	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive income (loss) were as follows: Years Ended December 31, 2024 2023 2022 Net foreign currency translation adjustment $ (32,590) $ 16,809 $ (4,799) Net change of cash flow hedge (see Note 20 for further information) Unrealized (loss) gain on cash flow hedge — (1,406) 3,564 Tax — 341 (868) Net of tax — (1,065) 2,696 Net change in postretirement benefit plan (see Note 15 for further information) Prior service loss (gain) arising during the period 206 132 (41) Amortization of prior service credit — — 9 Amortization of (gain) loss (10) 8 (2) Total before tax 196 140 (34) Tax (44) (39) (24) Net of tax 152 101 (58) Total other comprehensive (loss) income $ (32,438) $ 15,845 $ (2,161)
Schedule of Components of Accumulated Other Comprehensive (Loss)/Income	Accumulated other comprehensive loss at December 31, 2024 and 2023 consisted of the following: Foreign currency Cash flow hedge Postretirement benefit plan Total Balance December 31, 2023 $ 8,408 $ — $ 283 $ 8,691 Other comprehensive (loss) income (32,590) — 152 (32,438) Balance December 31, 2024 $ (24,182) $ — $ 435 $ (23,747)

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Schedule of Changes in Benefit Obligation	The actuarial recorded liabilities for such unfunded postretirement benefits are as follows: Change in benefit obligation: 2024 2023 Benefit obligation at beginning of year $ 1,395 $ 1,465 Service cost with interest to end of year 113 108 Interest cost 55 62 Participant contributions 20 23 Benefits paid (32) (30) Actuarial gain (29) (233) Benefit obligation at end of year $ 1,522 $ 1,395 Change in benefit obligation: 2024 2023 Benefit obligation at beginning of year $ 1,660 $ 1,589 Service cost with interest to end of year 72 65 Interest cost 54 65 Benefits paid (42) (188) Actuarial loss 488 80 Exchange rate changes (98) 49 Benefit obligation at end of year $ 2,134 $ 1,660
Schedule of Changes in Plan Assets	Change in plan assets: 2024 2023 Fair value of plan assets at beginning of year $ — $ — Employer contributions 12 7 Participant contributions 20 23 Benefits paid (32) (30) Fair value of plan assets at end of year $ — $ — Change in plan assets: 2024 2023 Fair value of plan assets at beginning of year $ 1,240 $ 1,196 Actual return on plan assets 216 56 Employer contributions 181 138 Benefits paid (42) (188) Exchange rate changes (74) 38 Fair value of plan assets at end of year $ 1,521 $ 1,240
Schedule of Amounts Recognized in Consolidated Balance Sheet	Amounts recognized in consolidated balance sheet: 2024 2023 Accumulated postretirement benefit obligation $ (1,522) $ (1,395) Fair value of plan assets — — Funded status (1,522) (1,395) Unrecognized prior service cost — 9 Unrecognized net loss (gain) 8 (2) Net amount recognized in consolidated balance sheet (after ASC 715) (included in $ (1,522) $ (1,395) Accrued postretirement benefit cost (included in "Other long-term obligations") N/A N/A Amounts recognized in consolidated balance sheet: 2024 2023 Benefit obligation $ (2,134) $ (1,660) Fair value of plan assets 1,521 1,240 Funded status (613) (420) Unrecognized prior service cost N/A N/A Unrecognized net (gain)/loss N/A N/A Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) $ (613) $ (420) Accrued postretirement benefit cost (included in other long-term obligations) N/A N/A
Schedule of Components of Net Periodic Benefit Cost	Components of net periodic benefit cost: 2024 2023 2022 Service cost with interest to end of year $ 113 $ 108 $ 79 Interest cost 55 62 26 Amortization of prior service cost — — 9 Amortization of (gain) loss (10) 8 (2) Total net periodic benefit cost $ 158 $ 178 $ 112 Components of net periodic benefit cost: 2024 2023 2022 Service cost with interest to end of year $ 72 $ 65 $ 44 Interest cost 54 65 17 Expected return on plan assets (40) (42) (37) Total net periodic benefit cost $ 86 $ 88 $ 24
Schedule of Estimated Future Employer Contributions and Benefit Payments	Estimated future employer contributions and benefit payments are as follows: Year 2025 $ 121 2026 106 2027 88 2028 95 2029 113 Years 2030-2034 741 Estimated future benefit payments are as follows: Year 2025 $ 1 2026 1 2027 1 2028 1 2029 1 Years 2030-2034 1,353
Schedule of Assumptions to Determine Benefit Obligation	Assumptions to determine benefit obligations: 2024 2023 Discount rate 4.85 % 4.15 % Assumptions to determine net cost: 2024 2023 2022 Discount rate 4.15 % 4.40 % 2.10 % Assumptions to determine benefit obligations: 2024 2023 Discount rate 3.35 % 3.45 % Assumptions to determine net cost: 2024 2023 2022 Discount rate 3.45 % 4.00 % 1.00 % Expected return on assets 3.25 % 3.25 % 3.25 %
Schedule of Pension Fund	The Company’s participation in this plan for the annual period ended December 31, 2024 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2024 and 2023 was affected by a 4.0% increase in the 2024 contribution rate. There have been no other significant changes that affect the comparability of 2024 and 2023 contributions. The Company does not represent more than 5% of the contributions to this pension fund. Pension EIN/Pension Pension Plan Protection Act Zone Status FIP/RP Status Contributions of Balchem Corporation Surcharge Expiration Date of Collective- 2024 2023 2024 2023 2022 Central States, 36-6044243 Critical as of 1/1/24 Critical as of 1/1/23 Implemented $1,073 $1,020 $939 No 7/12/2025

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lease Cost	Right of use assets and lease liabilities at December 31, 2024 and 2023 are summarized as follows: Right of use assets 2024 2023 Operating leases $ 15,320 $ 17,763 Finance lease 1,730 2,101 Total $ 17,050 $ 19,864 Lease liabilities - current 2024 2023 Operating leases $ 3,134 $ 3,949 Finance lease 194 272 Total $ 3,328 $ 4,221 Lease liabilities - non-current 2024 2023 Operating leases $ 12,967 $ 14,601 Finance lease 1,749 1,943 Total $ 14,716 $ 16,544 For the years ended December 31, 2024, 2023, and 2022, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions: Year ended December 31, 2024 2023 2022 Lease Cost Operating lease cost $ 5,456 $ 5,307 $ 4,478 Finance Lease cost Amortization of ROU asset 232 242 210 Interest on lease liabilities 105 115 125 Total finance lease 337 357 335 Total lease cost $ 5,793 $ 5,664 $ 4,813 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 5,454 $ 4,757 $ 4,269 Operating cash flows from finance leases 105 115 125 Financing cash flows from finance leases 216 222 177 $ 5,775 $ 5,094 $ 4,571 ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals $ 1,669 $ 6,365 $ 11,488 Weighted-average remaining lease term - operating leases 9.03 years 9.33 years 5.63 years Weighted-average remaining lease term - finance leases 8.37 years 9.07 years 9.95 years Weighted-average discount rate - operating leases 7.6 % 7.4 % 2.7 % Weighted-average discount rate - finance leases 5.1 % 5.0 % 5.0 %
Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases	Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2024 are as follows: Year 2025 $ 5,008 2026 4,399 2027 3,155 2028 2,393 2029 1,937 Thereafter 5,819 Total minimum lease payments $ 22,711
Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Finance Leases	Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2024 are as follows: Year 2025 $ 5,008 2026 4,399 2027 3,155 2028 2,393 2029 1,937 Thereafter 5,819 Total minimum lease payments $ 22,711

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Income (Loss) on Hedging Instruments	There were no gains and losses on hedging instruments recognized in accumulated other comprehensive income (loss) for the year ended December 31, 2024 as the derivative instruments settled on their maturity date of June 27, 2023. Gains and losses on our hedging instruments for the years ended December 31, 2023, and 2022 were recognized in accumulated other comprehensive income (loss) and categorized as follows: Location within Statements of Comprehensive Income 2023 2022 Cash flow hedge (interest rate swap), net of tax Unrealized (loss) gain on cash flow hedge, net $ (1,065) $ 2,696 Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment (1,455) 3,851 $ (2,520) $ 6,547

QUARTERLY FINANCIAL INFORMATI_2

QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	(In thousands, except per share data) 2024 2023 First Second Third Fourth First Second Third Fourth Net sales $ 239,659 $ 234,081 $ 239,940 $ 240,004 $ 232,540 $ 231,252 $ 229,948 $ 228,699 Gross margin 81,514 82,994 85,361 86,337 73,170 77,349 76,544 74,993 Earnings before income taxes 36,850 41,226 43,893 44,484 29,119 38,400 36,475 33,267 Net earnings 28,986 32,069 33,837 33,583 22,710 30,110 29,075 26,648 Basic net earnings per common share $ 0.90 $ 0.99 $ 1.05 $ 1.05 $ 0.71 $ 0.94 $ 0.91 $ 0.83 Diluted net earnings per common share $ 0.89 $ 0.98 $ 1.03 $ 1.03 $ 0.70 $ 0.93 $ 0.90 $ 0.82

BUSINESS DESCRIPTION AND SUMM_4

BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details)	Dec. 31, 2024
Minimum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years
Minimum | Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful lives	25 years
Maximum | Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	28 years

BUSINESS DESCRIPTION AND SUMM_5

BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details)	Dec. 31, 2024
Minimum | Customer relationships and lists
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	10 years
Minimum | Trademarks and trade names
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	2 years
Minimum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	5 years
Minimum | Regulatory registration costs
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	5 years
Minimum | Patents and trade secrets
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	15 years
Minimum | Other
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	2 years
Maximum | Customer relationships and lists
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	20 years
Maximum | Trademarks and trade names
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	17 years
Maximum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	12 years
Maximum | Regulatory registration costs
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	10 years
Maximum | Patents and trade secrets
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	17 years
Maximum | Other
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets	18 years

SIGNIFICANT ACQUISITIONS - Narr

SIGNIFICANT ACQUISITIONS - Narrative (Details) kr in Thousands				3 Months Ended	12 Months Ended
	Aug. 30, 2022 USD ($)	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Sep. 30, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired					$ 24,164,000	$ 1,252,000	$ 365,780,000
Contingent consideration liability					0	0	11,872,000
Goodwill					780,030,000	778,907,000	769,509,000
HNH
Business Acquisition [Line Items]
Goodwill					678,275,000	673,207,000
Goodwill percent	80%
ANH
Business Acquisition [Line Items]
Goodwill					23,974,000	24,469,000
Goodwill percent	20%
Bergstrom
Business Acquisition [Line Items]
Payment	$ 72,143,000				70,892,000
Total consideration	72,152,000
Cash acquired from acquisition	(773,000)
Cash paid for acquisitions, net of cash acquired	71,164,000
Contingent consideration liability					9,000
Post-closing payment				$ 910,000	910,000
Total payments					72,152,000
Working capital adjustment					341,000
Goodwill	31,550,000
Transaction and integration costs (credits)					(91,000)	(10,614,000)	4,604,000
Acquisition of transaction costs					(91,000)	(11,300,000)	(3,565,000)
Bergstrom | Former Shareholders
Business Acquisition [Line Items]
Payment	71,937,000
Total consideration	$ 71,946,000
Bergstrom | Customer relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired	15 years
Bergstrom | Corporate Trademark
Business Acquisition [Line Items]
Useful life of intangible assets acquired	2 years
Bergstrom | Product Trademarks
Business Acquisition [Line Items]
Useful life of intangible assets acquired	10 years
Bergstrom | Developed technology
Business Acquisition [Line Items]
Useful life of intangible assets acquired	12 years
Kappa
Business Acquisition [Line Items]
Payment | kr			kr 3,305,653
Total consideration		$ 333,112,000
Cash acquired from acquisition		(6,365,000)	(63,064)
Cash paid for acquisitions, net of cash acquired | kr			2,938,917
Goodwill		216,383,000
Transaction and integration costs (credits)					688,000	$ 533,000	(2,306,000)
Acquisition of transaction costs							$ (4,037,000)
Net gain on foreign currency exchange forward contracts		512,000
Kappa bank debt paid on acquisition date		333,112,000
Contingent consideration paid					$ 0
Kappa | Former Shareholders
Business Acquisition [Line Items]
Payment | kr			3,001,981
Total consideration		302,464,000
Cash paid for acquisitions, net of cash acquired		296,099,000
Kappa bank debt paid on acquisition date		302,464,000
Kappa | Former Shareholders' Lenders And Creditors
Business Acquisition [Line Items]
Payment | kr			kr 303,672
Total consideration		$ 30,648,000
Kappa | Customer relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired		15 years	15 years
Kappa | Corporate Trademark
Business Acquisition [Line Items]
Useful life of intangible assets acquired		2 years	2 years
Kappa | Product Trademarks
Business Acquisition [Line Items]
Useful life of intangible assets acquired		10 years	10 years
Kappa | Developed technology
Business Acquisition [Line Items]
Useful life of intangible assets acquired		12 years	12 years

SIGNIFICANT ACQUISITIONS - Fair

SIGNIFICANT ACQUISITIONS - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands			12 Months Ended
	Aug. 30, 2022	Jun. 21, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill			$ 780,030	$ 778,907	$ 769,509
Net decrease to contingent consideration liability and other post-closing payments			$ (91)	$ (11,300)	$ 0
Bergstrom
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash and cash equivalents	$ 773
Accounts receivable	4,699
Inventories	3,972
Property, plant and equipment	2,243
Right of use assets	866
Other assets	197
Accounts payable	(699)
Bank debt	(206)
Lease liabilities	(871)
Other liabilities	(462)
Goodwill	31,550
Total consideration on acquisition date and working capital adjustment	78,862
Net decrease to contingent consideration liability and other post-closing payments	(6,916)
Total consideration	72,152
Bergstrom | Former Shareholders
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Total consideration	71,946
Bergstrom | Former Bank
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Total consideration	206
Bergstrom | Customer relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	29,900
Bergstrom | Developed technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	4,600
Bergstrom | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	$ 2,300
Kappa
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash and cash equivalents		$ 6,365
Accounts receivable		8,036
Inventories		17,600
Property, plant and equipment		9,854
Right of use assets		3,349
Other assets		2,399
Accounts payable		(3,301)
Bank debt		(30,648)
Lease liabilities		(3,349)
Other liabilities		(4,461)
Deferred income taxes, net		(24,716)
Goodwill		216,383
Total consideration on acquisition date and working capital adjustment		307,013
Net decrease to contingent consideration liability and other post-closing payments		(4,037)
Net gain on foreign currency exchange forward contracts		(512)
Total consideration		333,112
Kappa | Former Shareholders
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Total consideration		302,464
Kappa | Former Shareholders' Lenders And Creditors
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Total consideration		30,648
Kappa | Customer relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		88,813
Kappa | Developed technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		15,643
Kappa | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		$ 5,046

SIGNIFICANT ACQUISITIONS - Sche

SIGNIFICANT ACQUISITIONS - Schedule of Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Sales [Abstract]
Kappa & Bergstrom actual results included in the Company's consolidated income statement	$ 59,532	$ 22,158
Pro forma combined net sales	922,439	982,021	$ 859,252
Net Earnings [Abstract]
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023	5,487	(5,359)
Supplemental pro forma combined financial information	$ 116,317	$ 110,181	$ 90,672

STOCKHOLDERS' EQUITY - Schedule

STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net earnings	$ (12,865)	$ (12,375)	$ (10,214)
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	1,716	1,900	1,302
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost	$ 14,960	$ 14,152	$ 11,922

STOCKHOLDERS' EQUITY - Stock-ba

STOCKHOLDERS' EQUITY - Stock-based Compensation (Details)		12 Months Ended
	Jun. 22, 2023 shares	Dec. 31, 2024 plan shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based compensation plans | plan		1
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grants (in shares)	2,400,000
Increase in amount approved (in shares)	800,000
Expiration period of options granted		10 years
2017 Plan | Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased under restricted stock purchase agreements, minimum (in shares)		70
Shares purchased under restricted stock purchase agreements, maximum (in shares)		54,000
2017 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards (in shares)		836,521

STOCKHOLDERS' EQUITY - Assumpti

STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Stock Options
Weighted Average Assumptions [Abstract]
Expected Volatility	28.40%	28.10%	30.30%
Expected Term (in years)	5 years	4 years 9 months 18 days	7 years 3 months 18 days
Risk-Free Interest Rate	4.10%	3.90%	2.80%
Dividend Yield	0.60%	0.50%	0.50%
Stock Options | Minimum
Weighted Average Assumptions [Abstract]
Vesting period	3 years
Stock Options | Maximum
Weighted Average Assumptions [Abstract]
Vesting period	5 years
Performance Shares | Employee
Weighted Average Assumptions [Abstract]
Expected Volatility	25%	32%	32%
Risk-Free Interest Rate	4.20%	4.20%	1.80%
Dividend Yield	0%	0.50%	0.50%
Initial total shareholder return percentage	10.30%	4.20%	(15.70%)
Cliff vesting percentage	100%
Vesting period	3 years
Restricted Stock | Employee
Weighted Average Assumptions [Abstract]
Vesting period	3 years
Restricted Stock | Non-employee director
Weighted Average Assumptions [Abstract]
Vesting period	3 years

STOCKHOLDERS' EQUITY - Stock Op

STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of year (in shares)	1,078	1,045	867
Granted (in shares)	113	109	239
Exercised (in shares)	(221)	(64)	(44)
Forfeited (in shares)	(8)	(11)	(17)
Cancelled (in shares)	0	(1)	0
Outstanding at end of year (in shares)	962	1,078	1,045
Exercisable at end of year (in shares)	603	720	654
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of year (in dollars per share)	$ 104.38	$ 99.82	$ 88.19
Granted (in dollars per share)	143.43	138.09	139.04
Exercised (in dollars per share)	77.81	81.98	73.58
Forfeited (in dollars per share)	139.64	131.79	124.89
Cancelled (in dollars per share)	0	138.07	0
Outstanding at end of year (in dollars per share)	114.81	104.38	99.82
Exercisable at end of period (in dollars per share)	$ 99.59	$ 88.49	$ 81.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Aggregate intrinsic value for outstanding stock options	$ 46,346	$ 47,889	$ 27,221
Weighted average remaining contractual term for outstanding stock options	5 years 9 months 18 days
Aggregate intrinsic value for exercisable stock options outstanding	$ 38,221
Weighted average remaining contractual term for exercisable stock options outstanding	4 years 4 months 24 days
Weighted-average fair value of options granted (in dollars per share)	$ 44.52	$ 40.91	$ 44.77
Total intrinsic value of stock options exercised	$ 18,631	$ 3,241	$ 2,713

STOCKHOLDERS' EQUITY - Informat

STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares Outstanding (in shares) | shares	962
Weighted Average Remaining Contractual  Term	5 years 9 months 18 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share)	$ 114.81
Number of Options Exercisable (in shares) | shares	603
Weighted Average Exercise Price of Options Exercisable (in dollars per share)	$ 99.59
$58.52 - $85.33
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	58.52
Range of exercise prices, maximum (in dollars per share)	$ 85.33
Shares Outstanding (in shares) | shares	222
Weighted Average Remaining Contractual  Term	3 years 1 month 6 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share)	$ 76.14
Number of Options Exercisable (in shares) | shares	222
Weighted Average Exercise Price of Options Exercisable (in dollars per share)	$ 76.14
$85.40 - $118.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	85.40
Range of exercise prices, maximum (in dollars per share)	$ 118.60
Shares Outstanding (in shares) | shares	212
Weighted Average Remaining Contractual  Term	4 years
Weighted Average Exercise Price of Options Outstanding (in dollars per share)	$ 101.92
Number of Options Exercisable (in shares) | shares	212
Weighted Average Exercise Price of Options Exercisable (in dollars per share)	$ 101.92
$118.96 - $150.85
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	118.96
Range of exercise prices, maximum (in dollars per share)	$ 150.85
Shares Outstanding (in shares) | shares	528
Weighted Average Remaining Contractual  Term	7 years 7 months 6 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share)	$ 136.24
Number of Options Exercisable (in shares) | shares	169
Weighted Average Exercise Price of Options Exercisable (in dollars per share)	$ 127.47

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unrecognized compensation cost related to non-vested shares	$ 20,035	$ 18,817	$ 20,791
Weighted-average period of recognition for unrecognized compensation cost	1 year 6 months
Estimated share-based compensation expense for current fiscal year	$ 16,900
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of year (in shares)	116	122	166
Granted (in shares)	51	40	46
Vested (in shares)	(39)	(42)	(82)
Forfeited (in shares)	(6)	(4)	(8)
Non-vested balance as of end of year (in shares)	122	116	122
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested balance as of beginning of year (in dollars per share)	$ 133.06	$ 124.42	$ 99.70
Granted (in dollars per share)	147.98	137.20	137.17
Vested (in dollars per share)	124.63	112.30	82.15
Forfeited (in dollars per share)	140.70	128.06	118.07
Non-vested balance as of end of year (in dollars per share)	$ 141.62	$ 133.06	$ 124.42
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of year (in shares)	76	70	69
Granted (in shares)	47	42	39
Vested (in shares)	(44)	(36)	(35)
Forfeited (in shares)	0	0	(3)
Non-vested balance as of end of year (in shares)	79	76	70
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested balance as of beginning of year (in dollars per share)	$ 135.25	$ 127.69	$ 110.72
Granted (in dollars per share)	152.28	139.66	114.22
Vested (in dollars per share)	106.57	98.84	53.17
Forfeited (in dollars per share)	0	0	84.09
Non-vested balance as of end of year (in dollars per share)	$ 150.73	$ 135.25	$ 127.69

STOCKHOLDERS' EQUITY - Repurcha

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)	3,763,038
Aggregate number of shares repurchased since inception (in shares)	3,142,028
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares)	38,922	32,558	252,304
Shares repurchased, average cost (in dollars per share)	$ 145.99	$ 137.29	$ 140.40

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 45,319	$ 39,517
Work in progress	4,510	3,960
Finished goods	80,973	66,044
Total inventories	130,802	109,521
Reserve for inventory	$ 4,207	$ 2,463

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 511,153	$ 488,835
Less: Accumulated depreciation	228,999	212,796
Property, plant and equipment, net	282,154	276,039
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment	11,690	11,787
Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment	106,954	104,363
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment	315,001	312,704
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 77,508	$ 59,981

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, excluding intangible assets	$ 282,154	$ 276,039
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, excluding intangible assets	204,397	203,692
Foreign Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, excluding intangible assets	$ 77,757	$ 72,347

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 28,211	$ 26,373	$ 24,033
Restructuring-related impairment and asset disposal charges	$ 521	$ 7,764	$ 0

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 780,030,000	$ 778,907,000	$ 769,509,000
Amortization of identifiable intangible assets	19,244,000	28,035,000	$ 27,271,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2024	16,417,000
2025	16,334,000
2026	15,816,000
2027	15,419,000
2028	15,017,000
Identifiable intangible assets	$ 0	$ 0

INTANGIBLE ASSETS - Goodwill (D

INTANGIBLE ASSETS - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 778,907	$ 769,509
Goodwill, acquired during period	19,376	341
Impact due to change in foreign exchange rates	(18,253)	9,057
Goodwill, end of period	780,030	778,907
Goodwill	780,030	778,907
HNH
Goodwill [Roll Forward]
Goodwill, beginning of period	673,207
Goodwill, end of period	678,275	673,207
Goodwill	678,275	673,207
ANH
Goodwill [Roll Forward]
Goodwill, beginning of period	24,469
Goodwill, end of period	23,974	24,469
Goodwill	23,974	24,469
Specialty Products
Goodwill [Roll Forward]
Goodwill, beginning of period	81,175
Goodwill, end of period	77,732	81,175
Goodwill	77,732	81,175
Other and Unallocated
Goodwill [Roll Forward]
Goodwill, beginning of period	56
Goodwill, end of period	49	56
Goodwill	$ 49	$ 56

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Intangible Assets Estimated Useful Lives (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Identifiable intangible assets [Abstract]
Gross Carrying Amount	$ 470,250	$ 479,235
Accumulated Amortization	305,200	288,023
Customer relationships and lists
Identifiable intangible assets [Abstract]
Gross Carrying Amount	354,051	362,032
Accumulated Amortization	$ 221,567	209,651
Customer relationships and lists | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	10 years
Customer relationships and lists | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	20 years
Trademarks and trade names
Identifiable intangible assets [Abstract]
Gross Carrying Amount	$ 50,971	50,286
Accumulated Amortization	$ 41,417	37,773
Trademarks and trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	2 years
Trademarks and trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	17 years
Developed technology
Identifiable intangible assets [Abstract]
Gross Carrying Amount	$ 40,074	41,184
Accumulated Amortization	$ 20,362	17,516
Developed technology | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	5 years
Developed technology | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	12 years
Other
Identifiable intangible assets [Abstract]
Gross Carrying Amount	$ 25,154	25,733
Accumulated Amortization	$ 21,854	$ 23,083
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	2 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (In years)	18 years

EQUITY-METHOD INVESTMENT (Detai

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) vote	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Number of votes | vote	2
Percentage of operating expenses to be absorbed	66.66%
Percentage of production offtake	66.66%
St. Gabriel CC Company, LLC
Schedule of Equity Method Investments [Line Items]
Ownership percentage in joint venture				66.66%
Loss relating to joint venture's expenses	$ 489	$ 509	$ 559
Capital contributions	269	290	$ 355
Carrying value of joint venture	$ 3,856	$ 4,076
St. Gabriel CC Company, LLC | Eastman Chemical Company
Schedule of Equity Method Investments [Line Items]
Ownership percentage in joint venture				33.34%

REVOLVING LOAN (Details)

REVOLVING LOAN (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jul. 27, 2022
Debt Instrument [Line Items]
Capitalized costs net of accumulated amortization	$ 743,000	$ 1,030,000
Amortization expense pertaining to capitalized costs	$ 287,000	287,000	$ 335,000
Credit Agreement
Debt Instrument [Line Items]
Interest rate	5.438%
Commitment fee percentage	0.15%
Unused portion of revolving loan	$ 360,000,000
Credit Agreement | Minimum
Debt Instrument [Line Items]
Commitment fee percentage	0.15%
Credit Agreement | Maximum
Debt Instrument [Line Items]
Commitment fee percentage	0.225%
Revolving loan | 2018 Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 550,000,000
Outstanding balance	$ 190,000,000	$ 309,569,000

NET EARNINGS PER COMMON SHARE_2

NET EARNINGS PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Earnings - Basic and Diluted	$ 33,583	$ 33,837	$ 32,069	$ 28,986	$ 26,648	$ 29,075	$ 30,110	$ 22,710	$ 128,475	$ 108,543	$ 105,367
Weighted average common shares - basic (in shares)									32,332,000	32,108,000	32,019,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)									386,000	340,000	374,000
Weighted average common shares - diluted (in shares)									32,718,000	32,448,000	32,393,000
Basic net earnings per common share (in dollars per share)	$ 1.05	$ 1.05	$ 0.99	$ 0.90	$ 0.83	$ 0.91	$ 0.94	$ 0.71	$ 3.97	$ 3.38	$ 3.29
Net earnings per share - diluted (in dollars per share)	$ 1.03	$ 1.03	$ 0.98	$ 0.89	$ 0.82	$ 0.90	$ 0.93	$ 0.70	$ 3.93	$ 3.35	$ 3.25
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)									230,302	354,619	371,513

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Effective tax rate	22.80%	20.90%	21.20%
Belgium earnings remitted	$ 0	$ 18,000
Incurred an income tax expense		20
Valuation allowance	25	22
Interest and penalties	939	(322)	$ (371)
Accrued interest and penalties	2,352	$ 1,413
State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 314

INCOME TAXES - Components of In

INCOME TAXES - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 30,208	$ 27,306	$ 26,423
Foreign	10,376	7,634	7,103
State	4,173	4,403	3,964
Deferred:
Federal	(2,442)	(7,737)	(7,532)
Foreign	(3,192)	(2,285)	(215)
State	(1,145)	(603)	(1,361)
Total income tax provision	$ 37,978	$ 28,718	$ 28,382

INCOME TAXES - Effective Income

INCOME TAXES - Effective Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Reconciliation [Abstract]
Income tax at Federal statutory rate	$ 34,955	$ 28,825	$ 28,087
State income taxes, net of Federal income taxes	2,284	2,513	1,862
Change in foreign tax reserves	2,146	0	0
Stock options	(1,904)	(1,004)	(676)
Foreign-derived intangible income (FDII)	(1,562)	(1,752)	(1,778)
Foreign rate differential	1,024	946	2,066
Other	1,035	(810)	(1,179)
Total income tax provision	$ 37,978	$ 28,718	$ 28,382

INCOME TAXES - Significant Port

INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Inventories	$ 2,437	$ 1,049
Share-based compensation	4,476	5,565
Lease liabilities	4,296	4,812
Research and development	12,838	12,653
Other	5,658	3,874
Total deferred tax assets	29,705	27,953
Deferred tax liabilities:
Amortization	(38,532)	(42,351)
Depreciation	(26,234)	(28,937)
Prepaid expenses	(306)	(421)
Foreign currency and interest rate swaps	(642)	(647)
Right of use assets	(4,032)	(4,574)
Other	(3,656)	(3,047)
Total deferred tax liabilities	(73,402)	(79,977)
Valuation allowance	(25)	(22)
Net deferred tax liability	$ (43,722)	$ (52,046)

INCOME TAXES - Income Tax Uncer

INCOME TAXES - Income Tax Uncertainties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of period	$ 4,650	$ 5,815	$ 5,881
Increases for tax positions of prior years	3,211	1,353	2,194
Decreases for tax positions of prior years	(1,141)	(2,518)	(2,260)
Balance at end of period	$ 6,720	$ 4,650	$ 5,815

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	3

SEGMENT INFORMATION - Business

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net sales	$ 240,004	$ 239,940	$ 234,081	$ 239,659	$ 228,699	$ 229,948	$ 231,252	$ 232,540	$ 953,684	$ 922,439	$ 942,358
Cost of sales									617,478	620,383	661,907
Gross margin	86,337	85,361	82,994	81,514	74,993	76,544	77,349	73,170	336,206	302,056	280,451
Operating Expenses									153,297	142,863	135,265
Earnings from operations									182,909	159,193	145,186
Interest expense, net									16,528	22,613	10,268
Other income									(72)	(681)	1,169
Nonoperating Income (Expense)									16,456	21,932	11,437
Earnings before income tax expense	44,484	43,893	41,226	36,850	33,267	36,475	38,400	29,119	166,453	137,261	133,749
Income tax expense									37,978	28,718	28,382
Net earnings	$ 33,583	$ 33,837	$ 32,069	$ 28,986	$ 26,648	$ 29,075	$ 30,110	$ 22,710	128,475	108,543	105,367
Operating Segments | HNH
Segment Reporting Information [Line Items]
Net sales									600,258	550,751	527,131
Cost of sales									378,411	366,539	373,063
Gross margin									221,847	184,212	154,068
Operating Expenses									85,890	81,793	71,943
Earnings from operations									135,957	102,419	82,125
Operating Segments | ANH
Segment Reporting Information [Line Items]
Net sales									214,710	238,326	262,297
Cost of sales									171,409	183,827	200,252
Gross margin									43,301	54,499	62,045
Operating Expenses									29,288	26,923	25,989
Earnings from operations									14,013	27,576	36,056
Operating Segments | Specialty Products
Segment Reporting Information [Line Items]
Net sales									132,749	125,965	131,438
Cost of sales									59,449	62,183	70,343
Gross margin									73,300	63,782	61,095
Operating Expenses									33,394	29,203	28,306
Earnings from operations									39,906	34,579	32,789
Other and Unallocated
Segment Reporting Information [Line Items]
Net sales									5,967	7,397	21,492
Cost of sales									8,209	7,834	18,249
Gross margin									(2,242)	(437)	3,243
Operating Expenses									4,725	4,944	9,027
Earnings from operations									$ (6,967)	$ (5,381)	$ (5,784)

SEGMENT INFORMATION - Busines_2

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Business segment assets	$ 1,575,371	$ 1,597,211
Operating Segments | HNH
Segment Reporting Information [Line Items]
Business segment assets	1,185,962	1,180,527
Operating Segments | ANH
Segment Reporting Information [Line Items]
Business segment assets	161,243	166,994
Operating Segments | SP
Segment Reporting Information [Line Items]
Business segment assets	161,283	168,307
Other and Unallocated
Segment Reporting Information [Line Items]
Business segment assets	$ 66,883	$ 81,383

SEGMENT INFORMATION - Depreciat

SEGMENT INFORMATION - Depreciation/Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 47,973	$ 54,935	$ 51,848
Other and Unallocated
Segment Reporting Information [Line Items]
Depreciation and amortization	1,028	1,213	3,928
HNH | Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization	31,668	38,568	33,728
ANH | Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization	8,233	7,876	6,685
SP | Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 7,044	$ 7,278	$ 7,507

SEGMENT INFORMATION - Capital E

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Capital expenditures	$ 35,148	$ 37,274	$ 49,086
Other and Unallocated
Segment Reporting Information [Line Items]
Capital expenditures	327	331	605
HNH | Operating Segments
Segment Reporting Information [Line Items]
Capital expenditures	17,570	26,415	33,668
ANH | Operating Segments
Segment Reporting Information [Line Items]
Capital expenditures	13,201	6,993	10,809
SP | Operating Segments
Segment Reporting Information [Line Items]
Capital expenditures	$ 4,050	$ 3,535	$ 4,004

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net sales	$ 240,004	$ 239,940	$ 234,081	$ 239,659	$ 228,699	$ 229,948	$ 231,252	$ 232,540	$ 953,684	$ 922,439	$ 942,358
United States
Disaggregation of Revenue [Line Items]
Net sales									723,300	689,601	682,238
Foreign Countries
Disaggregation of Revenue [Line Items]
Net sales									230,384	232,838	260,120
Product Sales Revenue
Disaggregation of Revenue [Line Items]
Net sales									951,947	919,951	939,166
Royalty Revenue
Disaggregation of Revenue [Line Items]
Net sales									$ 1,737	$ 2,488	$ 3,192

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Paid for Income Taxes and Interest [Abstract]
Income taxes	$ 42,643	$ 35,725	$ 33,016
Interest	17,697	25,933	11,879
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Dividends payable	28,510	25,717	23,129
Contingent consideration liability	$ 0	$ 0	$ 11,872

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net foreign currency translation adjustment	$ (32,590,000)	$ 16,809,000	$ (4,799,000)
Unrealized (loss) gain on cash flow hedge	0	(1,406,000)	3,564,000
Tax	0	341,000	(868,000)
Net of tax	0	(1,065,000)	2,696,000
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service loss (gain) arising during the period	206,000	132,000	(41,000)
Amortization of prior service credit	0	0	9,000
Amortization of (gain) loss	(10,000)	8,000	(2,000)
Total before tax	196,000	140,000	(34,000)
Tax	(44,000)	(39,000)	(24,000)
Net of tax	152,000	101,000	(58,000)
Other comprehensive (loss) income, net of tax	(32,438,000)	15,845,000	(2,161,000)
Currency swap
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net foreign currency translation adjustment	$ 0	(1,455,000)	3,851,000
Net change in postretirement benefit plan (see Note 15 for further information)
Net foreign currency translation adjustment tax		$ (471,000)	$ 1,236,000

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 1,053,984	$ 938,284	$ 877,015
Other comprehensive (loss) income	(32,438)	15,845	(2,161)
Ending balance	1,149,913	1,053,984	938,284
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	8,691	(7,154)	(4,993)
Other comprehensive (loss) income	(32,438)	15,845	(2,161)
Ending balance	(23,747)	8,691	$ (7,154)
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	8,408
Other comprehensive (loss) income	(32,590)
Ending balance	(24,182)	8,408
Cash flow hedge
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0
Other comprehensive (loss) income	0
Ending balance	0	0
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	283
Other comprehensive (loss) income	152
Ending balance	$ 435	$ 283

EMPLOYEE BENEFIT PLANS - Narrat

EMPLOYEE BENEFIT PLANS - Narrative (Details) $ in Thousands			12 Months Ended
	Aug. 30, 2022 plan	Jun. 21, 2022 plan	Dec. 31, 2024 USD ($) plan	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan			1
401(k) contributions | $			$ 4,644	$ 4,381	$ 4,363
Number of unfunded plans			2
Number of multiemployer benefit pension plans			1
Contribution rate increase			4%	4%
Deferred compensation liability | $			$ 11,470
Deferred compensation liability long-term | $			11,449	$ 10,188
Deferred compensation liability current | $			$ 21
Kappa
Defined Benefit Plan Disclosure [Line Items]
Number of defined contribution plans		1
Bergstrom
Defined Benefit Plan Disclosure [Line Items]
Number of defined contribution plans	1

EMPLOYEE BENEFIT PLANS - Change

EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Postretirement Medical Plans
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	$ 1,395	$ 1,465
Service cost with interest to end of year	113	108	$ 79
Interest cost	55	62	26
Participant contributions	20	23
Benefits paid	(32)	(30)
Actuarial gain	(29)	(233)
Benefit obligation at end of year	1,522	1,395	1,465
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	0	0
Employer contributions	12	7
Participant contributions	20	23
Benefits paid	(32)	(30)
Fair value of plan assets at end of year	0	0	0
Pension Plan
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	1,660	1,589
Service cost with interest to end of year	72	65	44
Interest cost	54	65	17
Benefits paid	(42)	(188)
Actuarial gain	488	80
Exchange rate changes	(98)	49
Benefit obligation at end of year	2,134	1,660	1,589
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,240	1,196
Actual return on plan assets	216	56
Employer contributions	181	138
Benefits paid	(42)	(188)
Exchange rate changes	(74)	38
Fair value of plan assets at end of year	$ 1,521	$ 1,240	$ 1,196

EMPLOYEE BENEFIT PLANS - Amount

EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Unrecognized prior service cost	$ 0	$ 9
Unrecognized net loss (gain)	8	(2)
Postretirement Medical Plans
Defined Benefit Plan Disclosure [Line Items]
Accumulated postretirement benefit obligation	(1,522)	(1,395)
Fair value of plan assets	0	0	$ 0
Funded status	(1,522)	(1,395)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations")	(1,522)	(1,395)
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated postretirement benefit obligation	(2,134)	(1,660)
Fair value of plan assets	1,521	1,240	$ 1,196
Funded status	(613)	(420)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations")	$ (613)	$ (420)

EMPLOYEE BENEFIT PLANS - Compon

EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Postretirement Medical Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost with interest to end of year	$ 113	$ 108	$ 79
Interest cost	55	62	26
Amortization of prior service cost	0	0	9
Amortization of (gain) loss	(10)	8	(2)
Total net periodic benefit cost	158	178	112
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost with interest to end of year	72	65	44
Interest cost	54	65	17
Expected return on plan assets	(40)	(42)	(37)
Total net periodic benefit cost	$ 86	$ 88	$ 24

EMPLOYEE BENEFIT PLANS - Estima

EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Postretirement Medical Plans
Defined Benefit Plan Disclosure [Line Items]
2025	$ 121
2026	106
2027	88
2028	95
2029	113
Years 2030-2034	741
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2025	1
2026	1
2027	1
2028	1
2029	1
Years 2030-2034	$ 1,353

EMPLOYEE BENEFIT PLANS - Define

EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Central States, Southeast and Southwest Areas Pension Fund
Multiemployer Plans [Line Items]
Contributions of Balchem Corporation	$ 1,073	$ 1,020	$ 939

EMPLOYEE BENEFIT PLANS - Assump

EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pension Plan
Benefit Obligatoins
Discount rate	3.35%	3.45%
Net Cost
Discount rate	3.45%	4%	1%
Expected return on assets	3.25%	3.25%	3.25%
Postretirement Medical Plans
Benefit Obligatoins
Discount rate	4.85%	4.15%
Net Cost
Discount rate	4.15%	4.40%	2.10%

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - Subsequent Event $ in Thousands	Jan. 31, 2025 USD ($)
EPA Civil penalty
Gain Contingencies [Line Items]
Payment for civil penalty and project benefits	$ 300
EPA Community spending
Gain Contingencies [Line Items]
Payment for civil penalty and project benefits	$ 350

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) financial_instrument	Dec. 31, 2023 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of financial instruments held for trading purposes | financial_instrument	0
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Related rabbi trust assets	$ 11,465	$ 10,188
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 1,040	$ 959

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Payments for services	$ 240,004	$ 239,940	$ 234,081	$ 239,659	$ 228,699	$ 229,948	$ 231,252	$ 232,540	$ 953,684	$ 922,439	$ 942,358
Receivables	119,662				125,284				119,662	125,284
Payables	54,745				55,503				54,745	55,503
St. Gabriel CC Company, LLC
Related Party Transaction [Line Items]
Services and raw materials									22,940	28,099	29,062
Receivables	3,893				8,314				3,893	8,314
Payables	2,831				6,050				2,831	6,050
St. Gabriel CC Company, LLC | Non-contractual monies owed
Related Party Transaction [Line Items]
Payables	$ 296				$ 329				296	329
St. Gabriel CC Company, LLC | Services Provided
Related Party Transaction [Line Items]
Payments for services									4,425	4,363	4,213
St. Gabriel CC Company, LLC | Raw Materials Sold
Related Party Transaction [Line Items]
Payments for services									$ 29,795	$ 34,219	$ 39,853

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) tranche	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Reasonably certain criterion renewal period	2 years
Number of lease tranches | tranche	4
Operating lease cost | $	$ 5,456	$ 5,307	$ 4,478
Years 1 and 2 | Minimum
Lessee, Lease, Description [Line Items]
Operating lease term	1 year
Discount rate	6.25%
Years 1 and 2 | Maximum
Lessee, Lease, Description [Line Items]
Operating lease term	2 years
Discount rate	6.76%
Years 3 and 4 | Minimum
Lessee, Lease, Description [Line Items]
Operating lease term	3 years
Discount rate	6.84%
Years 3 and 4 | Maximum
Lessee, Lease, Description [Line Items]
Operating lease term	4 years
Discount rate	7.35%
Years 5 through 9 | Minimum
Lessee, Lease, Description [Line Items]
Operating lease term	5 years
Discount rate	7.18%
Years 5 through 9 | Maximum
Lessee, Lease, Description [Line Items]
Operating lease term	9 years
Discount rate	7.69%
More than 10 years
Lessee, Lease, Description [Line Items]
Operating lease term	10 years
More than 10 years | Minimum
Lessee, Lease, Description [Line Items]
Discount rate	7.90%
More than 10 years | Maximum
Lessee, Lease, Description [Line Items]
Discount rate	8.41%

LEASES - Right-of-Use Assets an

LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Right of use assets
Operating Lease - ROU	$ 15,320	$ 17,763
Finance Leases - ROU	1,730	2,101
Total right-of-use assets	17,050	19,864
Operating leases liabilities - current	3,134	3,949
Finance lease liabilities - current	194	272
Total lease liabilities, current	3,328	4,221
Operating lease liabilities - non-current	12,967	14,601
Finance lease liabilities - non-current	1,749	1,943
Total lease liabilities, non-current	$ 14,716	$ 16,544

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lease Cost
Operating lease cost	$ 5,456	$ 5,307	$ 4,478
Amortization of ROU asset	232	242	210
Interest on lease liabilities	105	115	125
Total finance lease	337	357	335
Interest on lease liabilities	5,793	5,664	4,813
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	5,454	4,757	4,269
Operating cash flows from finance leases	105	115	125
Principal payments on finance lease	216	222	177
Cash flows from operating and finance leases	5,775	5,094	4,571
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals	$ 1,669	$ 6,365	$ 11,488
Weighted-average remaining lease term - operating leases	9 years 10 days	9 years 3 months 29 days	5 years 7 months 17 days
Weighted-average remaining lease term - finance leases	8 years 4 months 13 days	9 years 25 days	9 years 11 months 12 days
Weighted-average discount rate - operating leases	7.60%	7.40%	2.70%
Weighted-average discount rate - finance leases	5.10%	5%	5%

LEASES - Schedule of Aggregate

LEASES - Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating And Finance Lease, Liability, To Be Paid [Abstract]
2025	$ 5,008
2026	4,399
2027	3,155
2028	2,393
2029	1,937
Thereafter	5,819
Total minimum lease payments	$ 22,711

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) derivative	Dec. 31, 2023 USD ($) derivative	Dec. 31, 2022 USD ($) derivative	Jun. 21, 2022 derivative	May 28, 2019 USD ($)
Derivative [Line Items]
Proceeds from settlement of net investment hedge	$ 0	$ 2,740	$ 0
Interest Rate Swap | Interest Expense
Derivative [Line Items]
Net interest income (expense)	$ 0	$ 1,518	$ 400
Forward Contracts
Derivative [Line Items]
Contracts | derivative	0	0	4	4
Net gains on forward contracts			$ 512
Designated as hedge | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivatives					$ 108,569
Designated as hedge | Interest Rate Swap | Pay-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate					2.05%
Designated as hedge | Currency swap
Derivative [Line Items]
Notional amount of derivatives					$ 108,569
Designated as hedge | Currency swap | Pay-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate					0%
Designated as hedge | Currency swap | Receive-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate					2.05%
Designated as hedge | Currency swap | Interest Expense
Derivative [Line Items]
Net interest income (expense)	$ 0	$ 1,119	$ 2,250

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedge (interest rate swap), net of tax	$ 0	$ (1,065,000)	$ 2,696,000
Net investment hedge (cross-currency swap), net of tax	$ (32,590,000)	16,809,000	(4,799,000)
Losses and gains recognized in accumulated other comprehensive income (loss)		$ (2,520,000)	$ 6,547,000
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Unrealized (loss) gain on cash flow hedge, net of taxes of $341, and $868 at December 31, 2023, and 2022, respectively	Unrealized (loss) gain on cash flow hedge, net of taxes of $341, and $868 at December 31, 2023, and 2022, respectively	Unrealized (loss) gain on cash flow hedge, net of taxes of $341, and $868 at December 31, 2023, and 2022, respectively
Cash flow hedge (interest rate swap), net of tax		$ (1,065,000)	$ 2,696,000
Currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net change in postretirement benefit plan, net of taxes of $44, $39, and $24 at December 31, 2024, 2023 and 2022, respectively	Net change in postretirement benefit plan, net of taxes of $44, $39, and $24 at December 31, 2024, 2023 and 2022, respectively	Net change in postretirement benefit plan, net of taxes of $44, $39, and $24 at December 31, 2024, 2023 and 2022, respectively
Net investment hedge (cross-currency swap), net of tax	$ 0	$ (1,455,000)	$ 3,851,000

QUARTERLY FINANCIAL INFORMATI_3

QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 240,004	$ 239,940	$ 234,081	$ 239,659	$ 228,699	$ 229,948	$ 231,252	$ 232,540	$ 953,684	$ 922,439	$ 942,358
Gross margin	86,337	85,361	82,994	81,514	74,993	76,544	77,349	73,170	336,206	302,056	280,451
Earnings before income taxes	44,484	43,893	41,226	36,850	33,267	36,475	38,400	29,119	166,453	137,261	133,749
Net earnings	$ 33,583	$ 33,837	$ 32,069	$ 28,986	$ 26,648	$ 29,075	$ 30,110	$ 22,710	$ 128,475	$ 108,543	$ 105,367
Basic net earnings per common share (in dollars per share)	$ 1.05	$ 1.05	$ 0.99	$ 0.90	$ 0.83	$ 0.91	$ 0.94	$ 0.71	$ 3.97	$ 3.38	$ 3.29
Diluted net earnings per common share (in dollars per share)	$ 1.03	$ 1.03	$ 0.98	$ 0.89	$ 0.82	$ 0.90	$ 0.93	$ 0.70	$ 3.93	$ 3.35	$ 3.25

VALUATION AND QUALIFYING ACCO_2

VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allowance for Credit Losses
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ 908	$ 1,226	$ 928
Additions charged to costs and expenses	299	37	401
Adjustments/deductions	(298)	(355)	(103)
Ending balance	909	908	1,226
Inventory Reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	2,463	2,640	1,425
Additions charged to costs and expenses	4,123	2,450	6,786
Adjustments/deductions	(2,379)	(2,627)	(5,571)
Ending balance	$ 4,207	$ 2,463	$ 2,640